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List	of	recommendations	
• All	laboratories	performing	H&I	testing	for	allogeneic	HPC	transplantation	should	
follow	EFI	standards	and	be	accreditated	by	EFI	and	UKAS/CPA.	(Grade	1A)	
• HLA	typing	definitions	as	described	by	Nunes	et	al.	2011	and	here	should	be	used	
(Grade	1A)	
• HLA	typing	results	should	use	official	WHO	HLA	Nomenclature	(Grade	1A)	
• The	clinical	urgency	 should	be	made	available	 to	 the	 individual	performing	 the	
related	and	unrelated	donor	search	(Grade	1B)	
• HLA	 high	 resolution	 typing	 should	 be	 performed	 on	 potential	 matching;	
mismatching	and	haploidentical	related	donors	when	familial	haplotypes	cannot	
be	fully	assigned	(Grade	1A)	
• Patients	 and	 selected	 related	 donors	 should	 be	 typed	 for	HLA-A,	 -B,	 -C,	 -DRB1	
and	-DQB1	(+/-	DPB1)	(Grade	1A).	
• All	patients	and	donors	must	have	their	HLA	type	confirmed	on	a	second	sample	
pre-transplant	(Grade	1A).	
• The	patient	should	be	high	resolution	typed	prior	to	submitting	the	HLA	type	for	
an	unrelated	donor	search	(Grade	1A)	
• A	10/10	high	resolution	HLA-A,	-B,	-C,	-DRB1	and	–DQB1	matched	unrelated	
PBSC	or	bone	marrow	donor	should	be	used	where	possible	(Grade	1A).	
• Where	 a	 10/10	matched	 PBSC	 or	 bone	marrow	donor	 is	 not	 available	 a	 single	
mismatch	at	HLA-A,	-B,	-C,	-DRB1	or	–DQB1	is	acceptable	(Grade	1A).	
• Alternative	 progenitor	 cell	 donors	 (cord	 blood	 or	 haplo-identical)	 should	 be	
considered	early	 in	the	donor	search	when	a	patient	 is	unlikely	to	have	an	HLA	
matched	unrelated	donor	(Grade	1A).	
• HLA-DRB3,	 -DRB4,	 -DRB5	 typing	 should	 be	 performed	 and,	 when	 a	 choice	 of	
otherwise	equally	matched	and	appropriate	(e.g.	CMV	status)	donors	is	available,	
mismatches	for	these	should	be	minimized	(Grade	2A).																																																																																			
2016	01	28	HPC	Guideline	v1.0	
	
Page	3	of	60	
	
• For	unrelated	donor	selection,	HLA-DPB1	typing	should	be	performed	and	when	
a	choice	of	otherwise	equally	matched	and	appropriate	(e.g.	CMV	status)	donors	
is	available,	non-permissive	mismatches	should	be	minimised	(Grade	2C).	
• For	 mismatched	 related	 and	 unrelated	 donor	 selection,	 HVG	 mismatches	 are	
favoured	over	bi-directional	and	GVH	mismatches	(Grade	2C).	
• UCB	units	 should	be	HLA	 typed	 to	high	 resolution	HLA-A,	 -B,	 -C,	 -DRB1,	 -DQB1	
(Grade	1B	).	
• Selection	of	UCB	units	should	follow	national	consensus	guidelines	published	by	
Hough	et	al.	(Grade	1A).	
• HLA	 alloantibody	 testing	 of	 the	 recipient	 should	 be	 performed	 at	 the	 time	 of	
donor	search	and	should	be	repeated	at	the	time	of	donor	work-up	request	if	an	
HLA	mismatched	donor	is	selected	(Grade	1A).	
• The	clinical	 team	must	be	made	aware	of	any	HLA	alloantibody	 incompatibility	
for	a	selected	donor	(Grade	1A).		
• When	 a	 choice	 of	 equally	well	matched	 donors	 is	 available,	 avoid	 selection	 of	
donors	against	which	the	patient	has	HLA	alloantibodies	(Grade	1A).	
• HLA	alloantibody	 testing	 should	be	performed	 in	 cases	of	 failed	engraftment	 if	
the	donor	is	HLA	mismatched	(Grade	1B).	
• The	 guideline	 published	 by	 Emery	 et	 al.,	 2013	 recommending	 CMV	 matching	
between	patient	and	donor	should	be	followed	(Grade	1A).	
• Major	 ABO	 incompatibilities	 should	 be	 avoided	when	 there	 is	 a	 choice	 of	 HLA	
and	CMV	matched	donors	(Grade	1A)	
• Male	donors	should	be	preferentially	chosen	where	the	patient	has	multiple	HLA,	
CMV	and	ABO	matched	donors	(Grade	1C)	
• Younger	donors	should	be	preferentially	selected	(Grade	1B)	
• Homozygosity	 and	 novel	 HLA	 alleles	 identified	 within	 DNA	 extracted	 from	
patients	with	a	high	frequency	of	circulating	tumour	cells	should	be	confirmed	by	
family	studies	or		using	DNA	extracted	from	non-diseased	cells	(Grade	2A)	
• Individuals	actively	involved	in	the	provision	of	a	donor	selection	service	should	
undertake	 CPD	 and	 the	 service	 should	 be	 directed	 by	 an	 RCPath	 Fellow	 and	
Consultant	in	H&I	(Grade	1A)	
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Scope	
These	evidence-based	recommendations	expand	and	adapt	previous	guidance	 (Harvey	
et	al.	2012).	
	
Method		
This	guideline	was	produced	by	the	following	actions:	
i) A	 writing	 committee	 (authors	 of	 this	 manuscript)	 comprising	
Histocompatibility	 and	 Immunogenetics	 (H&I)	 scientists	 providing	 an	 H&I	
clinical	 service	 for	 related	 and	 unrelated	 donor	 haematopoietic	 progenitor	
cell	 transplantation	 was	 established.	 The	 chair	 of	 the	 committee,	 Ann-
Margaret	Little	was	appointed.	
ii) A	search	of	peer-reviewed	literature	to	June	31st	2015	was	undertaken	
iii) Recommendations	 were	 produced	 from	 evidence	 obtained	 from	 the	
literature	search.	Due	to	the	specialist	nature	of	histocompatibility	testing	in	
the	 context	 of	 haematopoietic	 progenitor	 cell	 allotransplantation	 there	 are	
few	large	and/or	multicentre	studies	 in	this	field	and	meta-analyses	are	not	
available.	 Some	 recommendations	 are	based	on	both	 literature	 review	and	
consensus	of	expert	opinion.	
iv) The	GRADE	nomenclature	was	used	to	evaluate	the	impact	of	evidence	and	
to	 define	 the	 strength	 of	 the	 recommendations	
[http://www.gradeworkinggroup.org/intro.htm#criteria]	
For	each	recommendation	the	quality	of	evidence	has	been	graded	as:		
A	(high)		
B	(moderate)		
C	(low)		
D	(very	low)		
For	 each	 recommendation,	 the	 strength	 of	 recommendation	 has	 been	
indicated	as	one	of:		
Level	1	(we	recommend)		
Level	2	(we	suggest)		
Not	graded	(where	there	is	not	enough	evidence	to	allow	formal	grading)		
Disclaimer:		
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These	 recommendations	 represent	consensus	opinion	 from	experts	 in	 the	 field	of	H&I	
within	the	United	Kingdom.	They	represent	a	snapshot	of	the	evidence	available	at	the	
time	of	writing.	This	evidence	may	become	superseded	with	time.		It	is	recognised	that	
recommendations	have	been	made	even	when	the	evidence	is	weak.		The	BSHI	cannot	
attest	 to	 the	 accuracy,	 completeness	 or	 currency	 of	 the	 opinions	 and	 information	
contained	 herein	 and	 does	 not	 accept	 any	 responsibility	 or	 liability	 for	 any	 loss	 or	
damage	caused	to	any	practitioner	or	any	 third	party	as	a	 result	of	any	reliance	being	
placed	on	this	guideline	or	as	a	result	of	any	inaccurate	or	misleading	opinion	contained	
in	the	guideline.	
	
Background	
	
The	 infusion	 (transplantation)	 of	 haematopoietic	 progenitor	 stem	 cells	 (HPC)	 into	 a	
patient	with	haematological	failure	due	to	malignant	or	non-malignant	causes	can	result	
in	successful	engraftment	of	donor	derived	HPC	which	undergo	haemopoiesis	to	replace	
the	malfunctioning	 cells	 of	 the	 patient’s	 immune	 system.	 HPC	 transplantation	 is	 also	
referred	to	as	bone	marrow	transplantation	(as	the	HPCs	may	be	taken	from	the	bone	
marrow	 of	 the	 donor)	 and	 stem	 cell	 transplantation.	 HPC	 transplants	 have	 been	
successfully	 performed	 since	 the	 late	 1960s.	 The	 effectiveness	 of	 these	 transplants	 in	
terms	 of	 patient	 overall	 survival	 and	 disease	 free	 survival	 has	 improved	 with	 each	
decade	due	to	more	accurate	histocompatibility	matching	between	donor	and	patient;	
improved	 patient	 conditioning	 protocols;	 use	 of	 therapeutic	 agents;	 prevention	 and	
treatment	of	infections	and	post-transplant	supportive	care.		
	
The	HPCs	that	are	transplanted	are	derived	from	the	following	sources:	
Autologous	HPC:		 the	cells	are	taken	from	the	patient		
Syngeneic	HPC:	 the	 donor	 is	 genetically	 identical	 to	 the	 patient	 i.e.	 an	
identical	twin	
Allogeneic	HPC:	 the	donor	is	not	genetically	identical	to	the	patient	and	
can	be	related	or	unrelated.	
This	guideline	describe	the	selection	of	donors	for	allogeneic	HPC	transplantation.	
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HLA	matching	donors	and	patients	in	HPC	transplantation	
Amongst	 the	 many	 factors	 that	 contribute	 to	 successful	 transplantation,	 the	 most	
significant	is	the	degree	of	histocompatibility	between	donor	and	patient.	Compatibility	
is	primarily	assessed	by	 the	degree	of	 sharing	of	genes	 that	encode	Human	Leucocyte	
Antigen	(HLA)	proteins	and	secondarily	by	additional	genetic	factors	such	as	blood	group	
and	non	genetic	factors	including	cytomegalovirus	(CMV)	infection	status.		
	
HLA	proteins	are	found	on	the	cell	surface	of	most	cells	within	the	human	body.	There	
are	two	different	classes	of	HLA	proteins:	HLA	class	I	(includes	HLA-A,	HLA-B	and	HLA-C	
proteins)	which	are	 found	on	 the	 surface	of	all	nucleated	cells	 and	platelets,	 and	HLA	
class	II	(including	HLA-DR,	HLA-DQ	and	HLA-DP	proteins)	which	are	normally	expressed	
on	 cells	 involved	 in	 antigen	 presentation	 such	 as	 dendritic	 cells	 and	 B-cells.	 The	
expression	of	HLA	class	 II	molecules	can	be	 induced	on	other	cell	 types	such	as	T-cells	
following	activation.	HLA	proteins	play	an	important	role	in	the	development	of	immune	
responses	against	non-self	antigens.	These	non-self	antigens	are	derived	 from	viruses;	
bacteria;	 abnormal	 proteins	 expressed	 by	 malignant	 cells	 and	 also	 non-self	 proteins,	
including	 HLA	 proteins	 expressed	 on	 transplanted	 cells	 and	 organs.	 Peptides	 derived	
from	 both	 self	 and	 non-self	 antigens	 are	 bound	 to	 HLA	 proteins	 within	 the	 antigen	
processing	pathways	and	the	bound	peptides	are	presented	to	receptors	expressed	by	
CD4+	and	CD8+	T-cells.	The	responding	T-cells	are	able	to	distinguish	between	self	and	
non-self	peptides	due	to	T-cell	education	pathways	occurring	during	T-cell	development	
in	 the	 thymus,	 resulting	 in	an	 immune	 response	being	 initiated	specifically	 to	non-self	
peptides	and	not	to	self	peptides.	HLA	proteins	also	interact	with	receptors	on	Natural	
Killer	(NK)	cells	and	this	interaction	plays	an	important	role	in	the	generation	of	immune	
responses	to	virally	infected	cells	and	malignant	cells.	
	
The	 genes	 encoding	 HLA	 proteins	 are	 located	 on	 the	 short	 arm	 of	 chromosome	 six	
within	 a	 gene	 dense	 region	 of	 the	 genome	 entitled	 the	 Major	 Histocompatibility	
Complex	 (MHC),	 so	 named	 due	 to	 the	 role	 the	 genes	 found	 in	 this	 region	 have	 in	
determining	 compatibility	 between	 donor	 and	 patient	 in	 transplantation.	 Unlike	most	
other	genes	in	the	human	genome,	HLA	genes	are	hyperpolymorphic	i.e.	there	are	many	
variations	within	the	HLA	gene	sequences	and	each	variant	is	called	an	allele.	Most	allele	
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differences	 are	 non-synonymous	 (change	 the	 amino	 acid	 composition	 of	 the	 HLA	
proteins).	Variations	 in	the	amino	acid	sequence	of	HLA	proteins	can	affect	the	way	 in	
which	self	and	non-self	peptides	are	presented	to	T-cells	and	how	they	are	recognised	
by	NK	cells.	
	
Each	human	expresses	at	least	six	HLA	proteins	(HLA-A,	HLA-B,	HLA-C,	HLA-DR,	HLA-DQ	
and	HLA-DP),	and	usually	twelve	different	proteins	as	most	individuals	inherit	different	
alleles	from	their	mother	and	father	(2xHLA-A,	2xHLA-B,	2xHLA-C,	2xHLA-DR,	2xHLA-DQ	
and	 2xHLA-DP).	 Possessing	 multiple	 different	 HLA	 proteins	 that	 are	 able	 to	 interact	
individually	 with	 immune	 cells	 enables	 our	 immune	 systems	 to	 respond	 rapidly	 and	
effectively	to	unwanted	pathogens	and	malignant	changes.			At	the	population	level,	the	
existence	 of	multiple	 individuals	with	 different	 variants	 of	 HLA	 proteins	 increases	 the	
chances	that	an	individual	will	exist	with	a	functional	HLA	phenotype	able	to	initiate	an	
immune	 response	 against	 a	 particular	 pathogen.	 Therefore	multiple	 polymorphic	 HLA	
genes	 are	 essential	 for	 the	 immune	 system	 to	 be	 able	 to	 defend	 its	 host	 against	 a	
plethora	 of	 non-self	 antigens.	 However	 this	 polygenic	 and	 polymorphic	 HLA	 system	
confers	 a	 significant	 obstacle	 when	 cells	 from	 one	 individual	 are	 transplanted	 into	
another.		
	
In	 a	 HPC	 transplant	 alloreactive	 cells	 of	 the	 patient	 can	 initiate	 an	 immune	 response	
against	 non-self	 antigens	 expressed	 by	 the	 donor	 cells	 causing	 rejection	 of	 the	 donor	
cells	seen	clinically	as	failed	engraftment.	Pre-transplant	conditioning	of	the	patient	with	
chemotherapy	and/or	irradiation	reduces	this	host	versus	graft	(HVG)	response	allowing	
the	 donor	 cells	 to	 engraft.	 Conversely,	 immune	 reactive	 cells	 from	 the	 donor,	 can	
initiate	an	attack	against	non-self	antigens	expressed	by	tissues	of	the	recipient	causing	
a	 graft	 versus	 host	 (GVH)	 immune	 response.	 This	 ‘acute	 Graft	 versus	 Host	 Disease’	
(aGVHD)	 is	 graded	 from	 I	 to	 IV	 (mild	 to	 severe)	 and	 involves	 multiple	 organs	 of	 the	
patient	 including	 skin,	 gut	 and	 liver	 with	 grade	 IV	 aGVHD	 being	 life-threatening.	 The	
GVH	response	can	also	be	beneficial	when	directed	specifically	to	malignant	antigens	i.e.		
Graft	versus	Leukaemia	(GVL).		
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The	 impact	of	matching	 the	HLA	alleles	of	patient	and	donor,	as	 is	 the	case	when	 the	
donor	 is	 an	 HLA	 matched	 sibling,	 contributes	 significantly	 to	 optimal	 outcome	 by	
reducing	the	alloreactions	that	contribute	to	HVG	and	GVHD	responses.		
	
Early	 data	 demonstrated	 better	 outcomes	 for	 patients	 receiving	 a	 transplant	 from	 an	
HLA	matched	 sibling	 donor	 compared	 to	 an	 unrelated	 donor.	 HLA	 typing	 to	 high	 and	
allele	level	resolution	has	resulted	in	improved	matching	between	unrelated	donors	and	
patients	leading	to	increased	survival	for	patients	receiving	unrelated	donor	transplants	
and	 giving	 comparable	 outcomes	 for	 some	 disease	 e.g.	 no	 effect	 of	 donor	 type	 on	
overall	 survival	 was	 observed	 in	 a	 cohort	 of	 108	 patients	 transplanted	 for	
haematological	 malignancies	 within	 a	 reduced	 intensity	 conditioning	 (RIC)	 regimen	
(Robin	et	al.,	2013).	An	earlier	study	comparing	transplant	outcomes	for	226	adult	acute	
myeloid	 leukaemia	 (AML)	 patients	 in	 first	 complete	 remission	 receiving	myeloablative	
unrelated	and	related	donor	transplants	during	1996-2007	demonstrated	the	probability	
of	 an	 unfavourable	 outcome	 in	 terms	 of	 overall	 survival,	 relapse	 and	 non	 relapse	
mortality	(NRM)	was	higher	for	patients	receiving	a	unrelated	donor	transplant	although	
not	 statistically	 significant,	 with	 patients	 receiving	 a	 9/10	 matched	 unrelated	 donor	
having	 similar	 outcomes	 to	 patients	 receiving	 a	 10/10	 matched	 unrelated	 donor	
transplant	 (Walter	 et	 al.,	 	 2010).	 Thus,	 selection	 of	 optimum	 related	 and	 unrelated	
donors	both	provide	good	outcomes	for	transplanted	patients.	
	
Testing	for	HLA	typing	and	alloantibody	identification	
	
HLA	testing	methodologies	
HLA	typing	and	alloantibody	identification	can	be	undertaken	by	different	methods.	It	is	
out	with	the	scope	of	this	guideline	to	advocate	which	methods	should	be	utilised.	All	
methods	used	to	determine	the	HLA	type	of	a	patient	and	donor	and	to	determine	the	
HLA	 alloantibody	 status	 of	 a	 patient	 undergoing	 transplantation	 must	 be	 validated	
within	 the	 laboratory	 where	 it	 is	 used.	 Within	 the	 United	 Kingdom	 HLA	 typing	 and	
alloantibody	identification	for	HPC	transplantation	must	be	performed	according	to	the	
standards	 for	 histocompatibility	 testing	 produced	 by	 the	 European	 Federation	 for	
Immunogenetics	(EFI)	and	must	be	undertaken	by	a	laboratory	accredited	by	the	United	
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Kingdom	 Accreditation	 Service	 (UKAS)/Clinical	 Pathology	 Accreditation	 (CPA),	 Ltd	 and	
EFI.	
	
Recommendation	
All	 laboratories	 performing	 H&I	 testing	 for	 allogeneic	 HPC	 transplantation	 should	
follow	EFI	standards	and	be	accreditated	by	EFI	and	UKAS/CPA.	(Grade	1A)	
	
HLA	typing	resolution	definitions	
	
Definitions	of	low,	intermediate,	high	and	allelic		
HLA	 alleles	 can	 be	 identified	 to	 varying	 degrees	 of	 resolution	 depending	 on	 the	
methodology	and	interpretation	used.	The	definitions	for	low,	high	and	allele	resolution	
typing	 as	 compiled	 by	 a	 joint	 international	 working	 party:	 the	 Harmonisation	 of	
Histocompatibility	 Typing	 Terms	Working	 Group,	 to	 define	 a	 consensual	 language	 for	
laboratories,	 physicians,	 and	 registries	 to	 communicate	 histocompatibility	 typing	
information	are	used	within	this	guideline	(Nunes	et	al.,	2011).	In	addition	we	accept	the	
following	definition	for	intermediate	resolution.	
	
Intermediate	resolution	
The	 term	 intermediate	 resolution	 can	 be	 applied	 when	 high	 resolution	 cannot	 be	
achieved	and	the	provided	HLA	type	includes	a	subset	of	alleles	sharing	the	digits	in	the	
first	field	of	their	allele	name	and	excludes	some	alleles	sharing	those	digits	e.g.	A*02:01	
or	A*02:02	or	A*02:07	or	A*02:20	but	 not	 other	A*02	 alleles.	 There	may	be	 cases	 in	
which	the	subset	of	alleles	 includes	one	or	more	alleles	within	a	group	beginning	with	
different	 digits	 but	 these	 alleles	 should	 be	 the	 exception	 eg.	 A*01:01	 or	 A*01:02	 or	
A*01:14	or	A:36:04	(Figure	1).	
	
Reporting	HLA	typing	results	
Due	 to	 the	 variety	of	 assays	 available	 to	a	 clinical	H&I	 laboratory	and	 the	 variation	 in	
resolution	 of	 HLA	 typing	 results	 generated,	 a	 standard	 format	 for	 reporting	 is	
encouraged	to	ensure	that	data	can	be	communicated	between	 laboratories	and	their	
users.	 The	 EFI	 standards	 provide	 instruction	 on	 the	 reporting	 of	 homozygosity,	
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heterozygosity	 and	 haplotype	 assignments.	 When	 reporting	 high	 resolution	 results	
containing	ambiguous	allele	combinations,	all	ambiguities	must	be	stated	on	the	report,	
or	 alternatively	 a	 comment	 made	 that	 ambiguities	 have	 not	 been	 excluded	 and	 are	
available	 to	 the	 user	 upon	 request.	 It	 is	 necessary	 for	 laboratories	 performing	 HLA	
typing	 to	define	 the	 level	of	 resolution	typing	 that	 they	are	undertaking	e.g.	 reporting	
intermediate	 resolution	 results	 as	 high	 resolution	 is	 inaccurate	 and	 could	 lead	 to	 in	
appropriate	selection	of	optimum	donor	by	missing	rare	and	novel	alleles.	
	
Official	 names	 are	 assigned	 to	 the	 HLA	 genes,	 antigens	 and	 alleles	 by	 the	 WHO	
Nomenclature	Committee	for	Factors	of	the	HLA	System	(Marsh	et	al.,	2010).	The	IPD-
IMGT/HLA	Database	is	the	official	repository	of	the	HLA	allele	sequences	(Robinson	et	al.,	
2015).	
	
Recommendations	
1. HLA	 typing	definitions	as	described	by	Nunes	et	al.	2011	and	here	 should	be	
used	(Grade	1A)	
2. HLA	typing	results	should	use	official	WHO	HLA	Nomenclature	(Grade	1A)	
	
Stage	of	disease,	time	to	transplant	and	HLA	matching.	
	
One	 of	 the	 earliest	 steps	 in	 donor	 selection	 is	 to	 consider	 the	 disease	 status	 of	 the	
patient.	Patients	with	a	slowly	progressing	disease	such	as	a	myelodysplastic	syndrome	
(MDS)	 allocated	 to	 international	 prognostic	 score	 system	 (IPSS)	 risk	 groups	 low	 and	
intermediate-1	 will	 have	 time	 to	 allow	 a	 search	 for	 the	 best	 matched	 related	 or	
unrelated	donor.	 In	these	cases	delayed	transplantation	to	source	the	optimum	donor	
can	maximise	overall	 survival.	However,	 for	patients	with	acute	 leukaemias	where	 the	
patient’s	 condition	 can	 rapidly	 deteriorate,	 there	 may	 only	 be	 a	 limited	 window	 of	
opportunity	to	transplant	when	the	patient	is	in	clinical	remission,	thus	limiting	the	time	
available	 for	 an	 extended	 related	 or	 unrelated	 donor	 search	 (Cutler	 et	 al.,	 2004).	 A	
patient	progressing	to	an	advanced	disease	usually	has	a	higher	mortality	risk	from	the	
disease	 than	 the	 added	 risk	 of	 a	 transplant	 from	 a	 single	 allele	 mismatch	 donor	 or	
alternative	 donor	 therapy	 such	 as	 umbilical	 cord	 blood	 (UCB)	 transplantation.	 The	
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impact	 of	 the	 time	 required	 to	 identify	 an	 optimum	matching	 donor	 has	 to	 be	 offset	
against	 the	 potential	 negative	 impact	 of	 the	 disease	 stage	 and	 progression	 and	 will	
determine	the	source	of	progenitor	cells	 selected	 for	 treatment	 (Weisdorf	2008).	 	The	
transplant	 team	must	 advise	 the	H&I	 laboratory	on	 the	 stage	of	 the	patient’s	 disease	
giving	 an	 indication	 of	 the	 clinical	 urgency	 and	 the	 H&I	 specialist	must	 advise	 on	 the	
likelihood	of	finding	an	optimum	high	resolution	matched	donor	within	the	time	frame	
defined	by	the	transplant	team.	
	
Recommendation	
1. The	clinical	urgency	should	be	made	available	to	the	individual	performing	the	
related	and	unrelated	donor	search	(Grade	1B)	
		
Histocompatibility	matching	for	related	donor	selection.	
	
The	 initial	 search	 for	 an	 HLA	 matched	 donor	 is	 usually	 within	 the	 patient’s	 family	
although	for	certain	genetic	diseases	a	related	donor	may	not	be	appropriate	if	they	are	
a	 carrier	of	 the	 same	genetic	mutation.	Although	 recent	 studies	 show	good	outcomes	
with	both	related	and	unrelated	donors	(Robin	et	al.,	2013)	there	is	still	an	advantage	in	
selecting	 a	 related	 donor	 over	 and	 above	 genetic	 compatibility.	 Related	 donors	 are	
usually	 quick	 to	 identify	 and	 are	 flexible	 in	 terms	 of	 timing	 the	 transplant,	 thus	
transplants	can	be	expedited	to	suit	the	patient’s	clinical	condition.	
	
HLA	matched	related	donor	selection	
There	 is	 a	 25%	 theoretical	 chance	 of	 finding	 an	 HLA	 identical	 sibling	 for	 a	 patient.	
However	 due	 to	 parents	 sharing	 common	 haplotypes,	 the	 actual	 number	 of	 patients	
identifying	an	HLA-A,	-B,	-C,	-DRB1,	-DQB1	matched	sibling	donor	is	closer	to	30%.	The	
selection	of	mismatched	and	haplo-identical	relatives	increases	the	options	of	finding	a	
donor	within	the	patient’s	family.			
	
The	availability	of	parental	HLA	typing	data	is	useful	for	assignment	of	haplotypes.	This	
data	 can	 usually	 be	 derived	 for	 paediatric	 patients	 but	 is	 rarely	 available	 for	 adult	
patients.	 The	 unequivocal	 determination	 of	 familial	 haplotypes	 enables	 the	
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identification	 of	 sibling	 donors	 that	 are	 HLA	 matches,	 without	 having	 to	 perform	
high/allele	 resolution	 HLA	 typing.	 This	 practice	 is	 referred	 to	 as	 ‘identity	 by	 descent’	
(Nunes	et	al.,	2011).	
	
Although	meeting	current	EFI	standards,	HLA-A,	-B	and	-DRB1	typing	of	siblings	(without	
parents)	 to	 identify	 potential	 matches,	 does	 not	 allow	 accurate	 determination	 of	
haplotypes	 and	 can	 lead	 to	 wrongly	 establishing	 presumptive	 matches.	 This	 is	 a	
particular	 concern	 when	 there	 is	 haplotype	 sharing	 between	 parents	 or	 apparent	
homozygosity	 (at	 low/intermediate	 resolution	 HLA	 typing)	 within	 a	 parent.	 This	 is	
illustrated	in	figure	2.	
	
When	haplotypes	cannot	be	established,	and	an	apparent	HLA	matching	related	donor	
has	been	identified,	or	in	the	case	of	families	where	the	parents	share	a	haplotype	or	a	
parent	is	apparently	homozygous	for	an	HLA	haplotype,	then	the	recipient	and	selected	
donor(s)	should	be	high/allele	resolution	typed	at	HLA-A,	 -B,	 -C,	 -DRB1	and	-DQB1	 loci	
(Figure	3).	HLA-DPB1	typing	can	also	be	used	to	aid	identification	of	genotype	matched	
donor	particularly	when	a	common	haplotype	is	within	the	family.	
	
All	 potential	 recombination	 events	within	 the	 HLA	 region,	 identified	within	 a	 patient,	
should	 be	 investigated	 and	 clarified	 by	 performing	 extended	 HLA	 typing	 on	 available	
family	members.		
	
HLA	mismatched	related	donor	selection.	
A	 single	 HLA	 antigen	 or	 allele	 mismatched	 related	 donor	 may	 be	 identified	 within	 a	
family,	 due	 to	 the	 parents	 sharing	 a	 closely	 matched	 haplotype	 or	 in	 the	 infrequent	
occurrence	 of	 genetic	 recombination.	 This	 related	 donor	 could	 be	 an	 acceptable	
mismatched	 donor	 in	 the	 absence	 of	 a	 fully	 matched	 related	 donor.	 Comparison	 of	
outcome	data	for	patients	receiving	10/10	matched	unrelated	donor	transplants	versus	
patients	 receiving	 9/10	 related	 donor	 transplants	 demonstrated	 no	 statistical	
differences	in	overall	survival,	disease	free	survival,	transplant	related	mortality,	relapse	
and	grade	III-IV	aGVHD.	A	lower	incidence	of	cGVHD	was	observed	in	the	9/10	matched	
related	donor	transplants	(Valcarcel	et	al.,	2011).		
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If	 HLA	 mismatched	 related	 donors	 are	 selected,	 the	 degree	 of	 mismatching	 must	 be	
accurately	determined	by	performing	high	resolution	typing	for	HLA-A,	-B,	-C,	-DRB1	and	
-DQB1	 as	 low/intermediate	 resolution	 typing	 could	 mask	 additional	 mismatches	
(Hansen	2012	and	Kanda	et	al.,	2012).	
		
Haploidentical	family	donors.	
A	 number	 of	 clinical	 protocols	 include	 the	 use	 of	 a	 single	 haplotype	 identical	 family	
member	 (haploidentical).	 This	 transplant	 format	 was	 pioneered	 by	 the	 Perugia	 and	
Frankfurt	groups	combined	with	a	‘megadose’	of	selected	stem	cells	(Aversa	et	al.,	2001	
and	Rizzieri	et	al.,	2007).	Current	protocols	include	the	post-transplant	administration	of	
cyclophosphamide	 to	 actively	 destroy	 proliferating	 alloreactive	 lymphocytes	 thus	
reducing	 the	 risk	 of	 severe	 GVHD	 caused	 by	 the	 HLA	mismatches	 (Chang	 and	Huang,	
2014	and	Reisner	et	al.,	2011).				
	
For	the	majority	of	paediatric	patients,	the	donor	will	either	be	the	patient’s	mother	or	
father.	For	adult	patients	this	choice	is	often	impracticable,	but	siblings	or	even	children	
may	be	considered.	
Haploidentical	transplantation,	by	definition	includes	HLA	mismatching.	Mismatching	for	
HLA	 proteins	 that	 interact	 with	 different	 NK	 cell	 inhibitory	 receptors	 (Killer-cell	
Immunoglobulin-like	Receptors,	KIR)	 such	as	HLA-C,	 can	 initiate	GVH	NK	cell	mediated	
alloreactions.	Post	transplantation,	NK	cells	will	be	generated	with	the	KIR	repertoire	of	
the	donor.	Included	within	this	NK	cell	population	will	exist	alloreactive	NK	cells	defined	
by	 their	 killing	 ability	 not	 being	 inhibited	 by	 the	HLA	proteins	 expressed	 by	 host	 cells	
including	 dendritic	 cells,	 T-cells	 and	 leukaemic	 cells	 resulting	 in	 a	 reduction	 in	 GVHD;	
prevention	of	graft	rejection	and	destruction	of	residual	leukaemic	cells	respectively.		
The	 latter	 graft	 versus	 leukaemia	 (GVL)	 effect	 could	 be	 enhanced	 if	 haploidentical	
donors	are	selected	to	encourage	NK	cell	mediated	alloreactivity.	The	role	of	KIR	and	KIR	
ligands	is	discussed	later.	
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As	 with	 all	 related	 donor	 transplants	 identification	 of	 haplotypes	 within	 the	 family	
and/or	high	resolution	typing	of	the	potential	haplotype	matched	donor	is	required.	All	
haplo-identical	donors	will	be	at	least	a	5/10	match	to	the	patient.	Additional	matching	
on	 the	 mismatched	 haplotype	 may	 be	 observed,	 however	 a	 beneficial	 impact	 of	
additional	 matching	 alleles	 was	 not	 demonstrated	 in	 a	 retrospective	 study	 of	 185	
recipients	 of	 nonmyeloablative	 HLA-haploidentical	 transplants	 for	 haematological	
malignancies	 (Kasamon	 et	 al.,	 2010).	 Thus,	 when	 multiple	 haplo-identical	 donors	 are	
available,	 the	donor	may	be	 selected	based	on	non-HLA	donor	 characteristics	 such	as	
CMV	status.	
	
Other	haploidentical	donor	factors		
Exposure	 of	 the	 patient	 to	 non-inherited	maternal	 antigens	 (NIMA)	 via	 transplacental	
trafficking	of	maternal	and	foetal	cells	during	pregnancy	may	result	in	tolerance	to	these	
antigens	when	present	on	cells	transplanted	to	the	patient	thus	reducing	HVG	immune	
responses.	Additionally	GVL	reactions	may	be	enhanced	resulting	in	lower	relapse	rates.	
In	 a	 study	 of	 118	 patients	 receiving	 haploidentical	 transplants,	 an	 increase	 in	 5-year	
event	free	survival	(50.6%	±7.6%	versus	11.1%	±4.2%;	p<0.001)	due	to	reduced	relapse	
and	 reduced	 transplantation	 related	mortality	was	observed	when	 the	donor	was	 the	
mother,	 compared	 to	 the	 donor	 being	 the	 father	 (Stern	 et	 al.,	 2008).	 This	 reduced	
relapse	 rate	 in	 recipients	of	maternal	HPC	 is	 independent	of	NK	 cell	 alloreactions	and	
supports	an	earlier	study	(Kolb	et	al.,	2005).	 In	contrast	multi-variate	analyses	of	1210	
haploidentical	transplants	in	China	has	shown	that	transplants	where	the	mother	is	the	
donor,	 have	 increased	 NRM,	 aGVHD	 and	 decreased	 survival	 compared	 to	 transplants	
where	the	father	is	the	donor.	In	this	study	a	sibling	donor	with	NIMA	mismatches	was	
concluded	 to	 be	 the	 optimum	 donor	 (Wang	 et	 al.,	 2014).	 Thus	 there	 is	 currently	
insufficient	 evidence	 in	 the	 literature	 to	 support	 the	 use	 of	 particular	 haplo-identical	
donors	 from	within	 the	 family	and	optimum	donor	 selection	 should	 take	 into	account	
non-HLA	factors.		
Related	cord	blood	donor	
HLA	 typing	 of	 potential	 related	 cord	 blood	 donors	 must	 be	 performed	 to	 the	 same	
resolution	as	undertaken	for	another	related	donor.		
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Final	donor	selection	
Both	 patient	 and	 the	 selected	 related	 donor	 must	 be	 HLA	 typed	 using	 a	 second	
independent	sample.	This	should	happen	as	early	as	possible	to	exclude	any	sampling	or	
laboratory	errors	and	must	take	place	prior	to	the	initiation	of	the	patient’s	conditioning	
protocol.	
The	second	HLA	 type	may	be	performed	by	 low/intermediate	 resolution	methods	and	
must	cover	at	a	minimum	HLA-A,	-B	and	-DRB1	loci.	
	
Recommendations	
1. HLA	 high	 resolution	 typing	 should	 be	 performed	 on	 potential	 matching;	
mismatching	 and	 haploidentical	 related	 donors	 when	 familial	 haplotypes	
cannot	be	fully	assigned	(Grade	1A)	
2. Patients	and	selected	related	donors	should	be	typed	for	HLA-A,	-B,	-C,	-DRB1	
and	-DQB1	(Grade	1A).	
3. All	 patients	 and	 related	 donors	 must	 have	 their	 HLA	 type	 confirmed	 on	 a	
second	sample	pre-transplant	(Grade	1A).	
	
Unrelated	adult	donor	selection	
	
For	 those	patients	without	an	 identified	matched/mismatched	related	donor,	a	search	
for	an	unrelated	donor	should	be	undertaken.	European	Society	for	Blood	and	Marrow	
Transplantation	 (EBMT)	 data	 shows	 that	more	 unrelated	 donor	 allogeneic	 transplants	
(54%)	than	HLA	matched	and	mismatched	sibling	donor	transplants	(46%)	took	place	in	
2012	(Passweg	et	al.,	2014).	
	
The	search	process	
For	some	patients	with	a	short	time-frame	to	transplant	it	may	be	necessary	to	embark	
on	the	unrelated	donor	search	simultaneously	whilst	searching	for	a	related	donor.	The	
decision	 to	 initiate	 an	 unrelated	 donor	 search	must	 be	made	 in	 conjunction	with	 the	
transplant	 team	 and	with	 the	 authorisation	 (Scotland)	 or	 consent	 (rest	 of	 UK)	 of	 the	
patient	to	permit	the	sharing	of	patient	personal	identification	details	with	the	national	
and	international	registries.	
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Within	 the	UK,	 there	 is	 an	aligned	unrelated	donor	 registry,	operated	by	 the	Anthony	
Nolan,	 providing	 search	 reports	 with	 details	 of	 donors	 from	 the	 Anthony	 Nolan;	 the	
British	 Bone	 Marrow	 Register	 (BBMR);	 the	 Welsh	 Bone	 Marrow	 Donor	 Register	
(WBMDR)	and	Delete	Blood	Cancer	UK.	Search	requests	are	sent	to	the	Anthony	Nolan	
and	a	search	report	of	UK	donors,	together	with	a	summary	report	of	the	results	from	a	
search	 of	 the	 international	 database	 of	 donor	 registries,	 Bone	 Marrow	 Donors	
Worldwide	(BMDW)	is	provided.	The	number	of	potential	matching	UK	donors	identified	
will	determine	whether	a	detailed	search	of	international	registries	is	required.	It	is	the	
responsibility	of	the	search	requester	to	establish	with	the	Anthony	Nolan	search	team,	
cut-off	 criteria	 in	 terms	 of	minimum	number	 of	 potential	matching	UK	donors	 before	
initiating	an	international	donor	search.	
	
The	most	useful	results	from	the	unrelated	donor	search	are	obtained	when	the	patient	
has	 been	 HLA	 typed	 to	 high/allele	 level	 resolution,	 as	 this	 allows	 elimination	 of	
mismatching	donors	from	the	search	summary.	
	
The	search	algorithm	
The	 World	 Marrow	 Donor	 Association	 (WMDA)	 has	 published	 a	 “framework	 for	 the	
implementation	of	HLA	matching	programs	in	haematopoietic	stem	cell	donor	registries	
and	cord	blood	banks”,	which	outlines	the	minimum	requirements	for	a	search	program	
(Bochtler	et	al.,	2011).	Essentially,	the	registry’s	matching	program	must	be	capable	of	
comparing	 donor-patient	 pairs	 irrespective	 of	 whether	 their	 HLA	 typing	 derives	 from	
serologic	or	DNA	based	methods.	These	comparisons	are	based	around	the	assignment	
of	a	search	determinant	to	each	HLA	allele	or	National	Marrow	Donor	Program	(NMDP)	
code	 based	 on	 files	 which	 are	 published	 on	 the	 HLA	 Nomenclature	 web	 site:	
http://hla.alleles.org/wmda.	
	
Once	the	patient’s	HLA	type	has	been	run	against	the	registry’s	database,	the	first	step	
in	processing	returned	donors	 is	 to	assign	a	match	grade	for	each	 locus,	where:	allelic	
match	>	serology	match	>	allelic	mismatch	>	serology	mismatch.	
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For	two	allelic	assignments	a1	and	a2,	there	are	three	possible	allelic	grades,	all	of	which	
can	be	distinguished	by	the	algorithm:	
	
• Nucleotide	Sequence	Match	-	a1	and	a2	have	identical	nucleotide	sequences	in	
all	 regions	 (exons	 and	 introns)	 underlying	 the	 current	 definition	 of	 the	 allele	
name,	e.g.	A*02:01:01:01	vs.	A*02:01:01:01.	
• Amino	Acid	 Sequence	Match	 -	a1	and	a2	have	 identical	amino	acid	sequences	
but	 differ	 within	 their	 nucleotide	 sequences,	 e.g.	 A*01:01:02	 vs.	 A*01:01:03,	
B*40:06:01:01	vs.	B*40:06:01:02.	
• Antigen	 Recognition	 Site	 Match	 -	 a1	 and	 a2	 differ	 within	 their	 amino	 acid	
sequence	but	not	within	the	regions	interacting	with	the	presented	antigen	and	
the	T-cell	receptor,	(encoded	by	exons	2-3	for	class	I,	and	exon	2	for	class	II).	e.g.,	
A*74:01	vs.	A*74:02.	
	
Once	the	scoring	is	complete,	the	list	of	donors	is	sorted	by	descending	match	count	and	
total	 score;	 additional	 sort	 parameters	 such	 as	 age,	 gender,	 and	 locus	 score	 are	
determined	by	the	user.	
	
UCB	unit	searching	is	based	on	a	similar	algorithm,	with	the	added	ability	to	match	on	
the	UCB	unit’s	NIMA	type.		
	
Currently	 the	 algorithm	 used	 in	 the	 UK	 by	 the	 Anthony	 Nolan	 shortlists	 potential	
matching	 donors	when	HLA-A,	 -B	 and	 -DRB1	 potentially	match	 but	 does	 not	 consider	
matching	beyond	the	first	 field	of	the	HLA	type	for	HLA-C	and	-DQB1,	when	typing	for	
these	 loci	 are	 available.	 The	 search	 requester	must	 check	 the	 true	 level	 of	 matching	
which	involves	decoding	NMDP	HLA	typing	codes	to	determine	whether	the	shortlisted	
potential	matching	donors	have	mismatches	at	HLA-C	and	-DQB1.		
Other	 registries	 such	 as	 the	 NMDP	 (USA	 registry)	 and	 ZKRD	 (German	 registry)	 use	
algorithms	that	match	to	high	resolution	for	HLA-A,	-B,	-C,	-DRB1	and	give	a	probability	
value	on	the	likelihood	of	a	donor	being	a	match	for	a	patient	based	on	HLA	allele	and	
haplotype	frequencies	in	the	donor	populations.	
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It	 is	 essential	 that	 the	 person	 interpreting	 search	 reports	 understands	 the	 algorithm	
used	by	the	various	different	registries	to	ensure	optimum	donor	selection.	
	
Genetic	factors	impacting	on	the	identification	of	a	HLA	matched	unrelated	progenitor	
cell	donor.	
The	 number	 of	 HLA-A,	 -B	 and	 -DRB1	 low	 resolution	 matched	 donors	 available	 for	 a	
patient	 following	 a	 BMDW	 search	 often	 reflects	 the	 likelihood	 of	 finding	 a	 high	
resolution	matched	unrelated	donor.		It	has	been	reported	that	Caucasoid	patients	have	
a	40-75%	chance	of	having	a	high	resolution	matched	donor	at	HLA-A,	-B,	-C,	-DRB1	and	
-DQB1	(10/10	match)	and	that	the	probability	of	finding	a	10/10	high	resolution	match	is	
highly	predictable	(Tiercy	et	al.,	2000;	Tiercy	et	al.,	2007;	Hirv	et	al.,	2009	and	Gragert	et	
al.,	2014).	The	chance	of	a	10/10	match	in	other	ethnic	groupings,	with	HLA	haplotypes	
that	 are	 less	well	 represented	on	 the	unrelated	donor	 registries,	 is	 significantly	 lower	
(Heemskerk	et	al.,	2005;	Schmidt	et	al.,	2009	and	Gragert	et	al.,	2014).	Hence,	patients	
are	 less	 likely	 to	 find	a	matched	donor	 from	an	ethnic	group	differing	 from	 their	own	
and	 patients	 with	 parents	 coming	 from	 differing	 ethnic	 groups	 (mixed	 race)	 are	 at	
increased	risk	of	not	finding	any	match.	
	
The	 use	 of	 “minimally”	 mismatched	 adult	 volunteer	 donors	 and	 cord	 blood	 units	
increases	significantly	the	likelihood	of	finding	a	usable	donor	(Gragert	et	al.,	2014	).	The	
frequencies	of	HLA-B	and	-C	and/or	HLA-DRB1	and	-DQB1	associations	in	differing	ethnic	
groups	are	available	for	some	donor	registries	for	comparison	with	the	HLA	type	of	the	
patient	(Cano	et	al.,	2007;	Kollman	et	al.,	2007;	Maiers	et	al.,	2007;	Gragert	et	al.,	2013	
and	Mack	et	al.,	2013)	and	these	tools	can	be	used	to	help	predict	how	likely	it	will	be	to	
find	a	match	for	a	patient.	
	
The	following	factors	must	be	considered	when	searching	for	a	high	resolution	matched	
unrelated	donor.	
• Commonly	found	HLA-B	and	-C	and/or	HLA-DRB1	and	-DQB1	associations	within	
the	patient’s	HLA	type	will	have	a	positive	 impact	on	the	likelihood	of	finding	a	
donor.	
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• Uncommon	haplotypes	present	in	the	patient	where	the	allele	of	one	locus	is	not	
in	 linkage	 disequilibrium	 with	 alleles	 of	 the	 neighbouring	 locus,	 such	 as	
uncommon	 HLA-B	 and	 -C	 and/or	 HLA-DRB1	 and	 -DQB1	 associations	 have	 a	
negative	impact	on	likely	donor	identification.	
• The	presence	of	an	allele	(in	the	patient)	with	a	frequency	of	<5%	within	the	low	
resolution	typed	potential	donors	(e.g.	B*44:05)	and	the	presence	of	an	allele	(in	
the	patient)	that	is	a	possible	match	for	low	resolution	donor	types	where	other	
alleles	having	frequencies	of	>10%	are	the	alternative	possible	mismatches	(e.g.	
B*35,	 B*44,	 DRB1*04,	 DRB1*11,	 DRB1*13).	 will	 negatively	 impact	 on	 the	
identification	of	a	matched	donor	
• The	presence	of	alleles	from	the	low	resolution	typing	group	HLA-B*51	and	B*18	
and	the	presence	of	alleles	B*27:05,	B*44:02	and	B*44:03	in	the	patient	have	an	
increased	risk	of	a	HLA-C	mismatch.	
• The	presence	of	alleles	from	the	low	resolution	typing	group	HLA-DRB1*04	and	
DRB1*07	in	the	patient	have	a	raised	risk	of	a	HLA-DQB1	mismatch.	
	
HLA	matching	requirements	for	unrelated	donor	transplants	
Multiple	 studies	 have	 reported	 optimum	 transplant	 outcome	 is	 achieved	 when	 the	
patient	 and	 donor	 are	matched	 for	HLA-A,	 -B,	 -C	 and	 -DRB1	 alleles	 (Petersdorf	et	 al.,	
2001;	Morishima	et	al.,	2002;	Petersdorf	et	al.,	2004;	Flomenberg	et	al.,	2004;	Lee	et	al.,	
2007;	Woolfrey	et	al.,	2011).	
	
The	role	of	HLA-DQ	matching	is	less	well	supported,	NMDP	data	from	3857	transplants	
for	malignant	 disease	 (Lee	 et	 al.,	 2007),	 showed	 that	 individual	mismatches	 for	 HLA-
DQB1	had	no	impact	on	survival.	However	if	the	DQB1	mismatch	was	associated	with	an	
additional	mismatch	e.g.	7/8	or	6/8	HLA-A,	 -B,	 -C,	 -DRB1	mismatch,	then	there	was	an	
association	with	 poorer	 survival	 albeit	 not	 statistically	 significant.	 Although	HLA-DQB1	
mismatching	did	not	reach	significance	in	relation	to	survival,	in	a	recent	German	study	
(Fürst	 et	 al.,	 2013),	 HLA-DQ	 antigen	 mismatching	 achieved	 a	 higher	 hazards	 risk	 for	
survival	compared	to	HLA-DQ	antigen	matches.	
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Overall,	single	mismatches	are	deemed	acceptable,	with	multiple	mismatches	conferring	
significantly	worse	outcomes	(Crocchiolo	et	al.,	2009a)	with	the	effect	observed	greater	
when	the	patient	had	acute	leukaemia	and	was	transplanted	early	during	first	remission	
compared	to	patients	with	advanced	disease.		
	
Impact	of	mismatches	at	individual	HLA	loci	on	transplant	outcome		
There	 is	 no	 consensus	 regarding	 which	 of	 the	 HLA-A,	 -B,	 -C,	 -DRB1	 loci	 are	 more	
detrimental	 to	mismatch.	 HLA-A	 and	 -DRB1	mismatching	were	 reported	 as	 being	 less	
well	 tolerated	 compared	 to	 HLA-B	 and	 -C	 mismatches	 in	 a	 NMDP	 study	 with	 all	
mismatches	reducing	overall	survival	at	1	year	by	9-10%	(Lee	et	al.,	2007).	 In	contrast,	
the	 Japanese	 registry	 reported	 transplants	with	 HLA-A	 and	 -B	mismatches	 had	worse	
survival	than	HLA-C	and	-DRB1	mismatches	(Morishima	et	al.,	2002).	HLA-B	mismatches	
were	 associated	 with	 a	 higher	 risk	 of	 aGVHD	 II-IV	 in	 an	 Italian	 study	 of	 805	 patients	
transplanted	for	haematological	malignancies	(Crocchiolo	et	al.,	2009a)	whereas	HLA-C	
antigen	mismatches	were	associated	with:	lower	leukaemia	free	survival;	increased	risk	
for	 mortality	 and	 grade	 III-IV	 GvHD	 in	 an	 NMDP/	 Centre	 for	 International	 Blood	 and	
Marrow	 Transplant	 Research	 	 (CIBMTR)	 study	 of	 1933	 patients	 transplanted	 with	
haematological	malignancies	(Woolfrey	et	al.,	2011).	The	variability	in	the	outcomes	of	
these	 studies	 can	be	attributed	 to:	differences	 in	 study	design;	patient	demographics;	
source	of	stem	cells,	including	T-cell	depletion;	differences	in	HLA	polymorphism	within	
groups	of	patients	of	different	ethnicities;	use	of	serotherapy	and	GvHD	prophylaxis.	
	
A	retrospective	analysis	of	2646	T-cell	replete	transplants	performed	for	haematological	
malignancies	 in	 Germany	 has	 been	 performed	 (Fürst	 et	 al.,	 2013).	 All	 patients	 and	
donors	were	HLA	typed	to	high	resolution.	The	 impact	of	mismatches,	defined	at	both	
high	 (allele)	 and	 low	 (antigen)	 resolution,	 on	 overall	 survival;	 disease	 free	 survival;	
relapse,	 transplant	 related	 mortality	 and	 primary	 graft	 failure	 was	 analysed.	 Overall	
allele	and	antigen	mismatches	did	not	correlate	with	a	differential	impact	on	transplant	
outcome.	This	finding	supports	previous	work	published	by	Lee	et	al.,	(2007)	(except	for	
HLA-C	where	allele	mismatches	were	not	associated	with	poorer	outcome	by	Lee	et	al.)	
and	Crocchiolo	et	al.,	(2009).	Thus,	any	type	of	mismatch	can	have	a	negative	impact	on	
outcome.		
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Mismatches	at	alleles	of	either	of	HLA-A,	-B,	-C,	-DRB1	and	-DQB1	were	associated	with	
a	decrease	in	overall	survival	(only	significant	for	HLA-A,	-B,	-C	and	-DRB1);	a	decrease	in	
disease	 free	 survival	 (significant	 for	 HLA-C)	 and	 an	 increase	 in	 transplant	 related	
mortality	 (significant	 for	 HLA-A,	 -B,	 -C	 and	 –DRB1).	 Of	 all	 associations	 observed,	 the	
most	 significant	 were	 with	 HLA-C	 antigen	 mismatches,	 affecting	 overall	 survival	 and	
disease	free	survival,	with	HLA-B	allele	mismatching	being	the	most	significant	affecting	
transplant	 related	 mortality.	 HLA-C	 allele	 mismatches	 gave	 consistently	 lower	 hazard	
risks	for	the	outcomes	studied	suggesting	that	there	may	be	permissive	mismatching	at	
the	HLA-C	allele	 level	(Fürst	et	al.,	2013).	Permissive	HLA-C	mismatching	has	also	been	
described	for	HLA-C*03:03	and	C*03:04.	The	transplant	outcome	for	patients	receiving	a	
7/8	 (C*03:03/C*03:04)	 mismatched	 transplant	 was	 not	 significantly	 different	 from	
patients	receiving	a	8/8	matched	transplant	(Fernandez-Viña	et	al.		2014).		
	
The	impact	of	HLA-C	antigen	versus	allele	mismatches	has	been	further	elucidated	in	a	
study	 of	 1975	 HLA-C	 only	 mismatched	 (matched	 HLA-A,	 -B,	 and	 -DRB1)	 transplants	
(Petersdorf	et	al.,	2014).	The	 level	of	expression	of	 the	mismatched	HLA-C	alleles	was	
assessed	using	median	fluorescence	 intensity	(MFI)	data	procured	from	previous	study	
of	 healthy	 and	Human	 Immunodeficiency	Virus	 (HIV)	 infected	 individuals	 (Apps	et	 al.,	
2013).	 Patients	 with	 low	 expressing	 mismatched	 HLA-C	 alleles	 and	 antigens	 were	
associated	with	a	decreased	risk	of:	aGVHD	III-IV;	NRM	and	overall	mortality	but	with	no	
impact	 on	 relapse	 compared	 to	 the	 non-shared	 HLA-C	 being	 a	 low	 expressor.	 The	
presence	 of	 a	 high	 expressing	 mismatched	 (non-shared)	 HLA-C	 allele/antigen	 in	 the	
donor	was	also	associated	with	an	increase	in	NRM	and	mortality,	but	with	no	effect	on	
aGvHD	 or	 relapse.	 The	 allele	mismatches	 were	 predominantly	 C*07	 and	 C*03,	 which	
have	been	shown	to	have	low	levels	of	expression,	and	these	mismatches	may	account	
for	 the	 previously	 reported	 permissive	 HLA-C	 mismatches.	 Mismatching	 for	 lower	
expressing	 HLA-C	 alleles	 of	 the	 patient,	 compared	 to	 higher	 expressing	 HLA-C	 alleles	
may	 lower	 the	 GVH	 immune	 response	 supporting	 selection	 of	 mismatches	 for	 lower	
expressed	allotype	over	mismatches	for	high	expressed	alleles,	and	avoidance	of	HLA-C	
mismatched	 donors	 for	 patients	 with	 two	 highly	 expressed	 allotypes.	 This	 study	 also	
demonstrated	a	higher	risk	in	double	mismatch	(8/10)	transplants	involving	a	class	I	and	
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II	 mismatch	 compared	 to	 double	 class	 I	 or	 double	 class	 II.	 	 Other	 research	 has	
highlighted	the	impact	of	the	HLA-C	bearing	haplotype	on	HLA-C	expression	which	could	
differ	in	HLA-C	mismatched	transplants	(Bettens	et	al.,	2014)		
	
One	of	the	problems	making	it	difficult	to	define	an	accurate	risk	estimate	for	single	loci	
mismatches	is	the	extensive	polymorphism	exhibited	at	HLA	loci.	Mismatches	at	any	loci	
may	 involve	one	 versus	 10	 versus	 20	 amino	acid	mismatches	 e.g.	A*01:01	 v	A*02:01;	
A*01:01	v	A*03:01;	A*01:01	v	A*23:01	and	not	all	mismatches	at	a	given	loci	will	have	
equal	effects	on	GVL	and	GVH	immune	responses	post	transplant.	It	has	been	calculated	
that	 a	 database	 of	 11,000	 to	 1.3	 million	 transplants	 would	 be	 required	 to	 provide	
sufficient	 statistical	 power	 to	 detect	 an	 association	 between	 particular	 HLA	 allele	
mismatches	and	survival	(Baxter-Lowe	et	al.,	2009).	
		
	
Impact	of	individual	amino-acid	substitutions	on	transplant	outcome	
The	 impact	on	transplant	outcomes	(acute,	chronic	GVHD,	transplant	related	mortality	
(TRM),	 relapse	 and	 overall	 survival)	 of	 amino	 acid	 substitution	 at	 peptide	 binding	
positions	9,	99,	116	and	156,	and	KIR	binding	position	at	amino	acid	77	was	studied	in	a	
multivariate	 analysis	 of	 a	 heterogenous	 cohort	 of	 patients	 transplanted	 for	
haematological	malignancies	(Pidala	et	al.,	2013).	Individual	mismatches	at	residues	99	
and	116	within	HLA-C	were	associated	with	an	 increased	TRM	and	severe	acute	GVHD	
respectively.	A	mismatch	at	residue	9	within	HLA-B	was	associated	with	an	 increase	 in	
chronic	GVHD.	None	of	the	mismatches	studied	had	an	affect	on	outcome	when	located	
within	HLA-A.	
	
In	the	study	of	Petersdorf	et	al.,	(2014),	patients	with	HLA-C	mismatches	at	residue	116	
had	 an	 increased	 risk	 of	 aGVHD	 compared	 to	 residue	 116	 matched	 patients	 and	 a	
slightly	higher	risk	of	overall	mortality.	These	 findings	were	not	statistically	significant.	
However	 the	 incidence	 of	 NRM	 was	 found	 to	 increased	 in	 patients	 that	 were	
mismatched	for	residue	116	as	the	expression	of	the	HLA-C	mismatch	also	increased	(HR,	
1.31;	 95%CI,	 1.09-1.58;	 P=0.004).	 This	 was	 not	 observed	 in	 patients	 mismatched	 for	
higher	expressing	HLA-C	alleles	that	were	residue	116	matched	(HR,	0.98;	95%	CI,	0.78-
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1.23;	P=0.88).	Patients	receiving	HLA-C	mismatches	with	specific	amino	acid	differences	
at	 KIR	 interacting	 residues	 77	 and	 80,	 had	 HLA-C	mismatches	 with	 higher	 expression	
compared	 to	 patients	 with	 matching	 residues	 77	 and	 80.	 No	 statistical	 significant	
associations	with	aGVHD,	overall	mortality	or	NRM	were	identified,	although	similar	to	
mismatching	 at	 residue	 116,	 the	 risk	 of	 NRM	 increased	 as	 the	 HLA-C	 mismatch	
expression	 levels	 increased	 for	 the	 patients	 receiving	 residue	 77	 and	 80	mismatched	
transplants	(HR,	1.38;	95%	CI,	1.14-1.67;	P	=	0.0009).	This	was	not	observed	for	patients	
receiving	residue	77	and	80	matched	transplants	(HR,	1.01;	95%	CI,	0.82-1.24;	P	=	0.91).	
Thus	mismatching	 for	 allotypes	 that	 are	 highly	 expressed	 and	 contain	mismatches	 at	
residues	77	and	80	could	initiate	donor	NK	cell	alloreactivity.		
	
Therefore	if	a	choice	of	mismatched	donors	is	available,	consideration	of	the	location	of	
the	 mismatched	 amino	 acid	 residues	 and	 avoidance	 of	 the	 described	 non-permissive	
mismatches	 may	 contribute	 to	 better	 outcome.	 For	 HLA-C	 mismatches,	 apparent	
expression	levels	may	also	be	considered.	
	
Impact	of	HLA-DPB1	mismatching	
Recombination	hotspots	are	located	between	HLA-DQB1	and	-DPB1	genes	(Cullen	et	al.,	
1997),	therefore	matching	patients	and	unrelated	donors	with	common	HLA-A,	-C,	-B,	-
DRB1,	 -DQB1	haplotypes,	does	not	necessarily	 implicate	matching	 for	HLA-DPB1	and	 -
DPA1	alleles.	 It	 is	 reported	 that	within	 families	up	 to	5%	of	otherwise	10/10	matched	
siblings	will	 also	be	HLA-DPB1	mismatched	attributed	 to	 recombination	between	HLA-
DQ	and	-DP	genes	(Büchler	et	al.,	2002).	HLA-DP	specific	T-cells	have	been	detected	and	
associated	with	both	GVL	(Rutten	et	al.,	2008,	Rutten	et	al.,	2013)	and	GVHD	(Stevanovic	
et	 al.,	 2013)	 supporting	 the	 direct	 role	 of	 HLA-DP	 proteins	 in	 the	 immune	 responses	
occurring	between	patient	and	donor	cells	post	transplant.	
	
Analysis	of	the	 impact	of	HLA-DPB1	matching	and	mismatching	on	transplant	outcome	
has	 been	 studied	 in	 both	 single	 centre	 and	 multi-centre	 studies.	 In	 an	 analysis	 of	 a	
heterogenous	 international	 cohort	 of	 transplant	 recipients,	 allelic	 DPB1	 mismatches	
were	 shown	 to	 offer	 a	 GVL	 advantage	 via	 a	 reduction	 in	 relapse,	 but	 this	 was	 also	
associated	with	 increased	 aGVHD	 and	 a	 suggestive	 increase	 in	mortality	 (Shaw	et	 al.,	
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2007).	In	an	NMDP	study,	there	was	no	significant	association	of	single	or	double	HLA-
DPB1	allele	mismatches	with	survival	compared	to	no	DPB1	mismatches	in	an	otherwise	
HLA-A,B,C,DRB1	matched	group	of	recipients.	An	 increased	risk	of	TRM	and	decreased	
risk	of	relapse	was	suggestive	in	this	study	albeit	not	significant	(Lee	et	al.,	2007).			
	
In	 a	 UK	 multicentre	 study,	 the	 impact	 of	 DPB1	 allele	 matching	 was	 associated	 with	
better	overall	survival	in	patients	transplanted	with	early	leukaemia	but	not	in	patients	
transplanted	with	late	stage	disease	(Shaw	et	al.,	2010),	supporting	other	studies	where	
the	effect	of	HLA	matching	 is	not	as	strong	 in	patients	 transplanted	at	 late	stage.	This	
effect	 was	 restricted	 to	 patients	 receiving	 10/10	 matched	 transplants,	 as	 a	 survival	
advantage	was	observed	in	patients	receiving	9/10	matched	transplants	which	also	had	
a	single	DPB1	mismatch.	This	finding	also	held	in	multivariate	analysis	(OR	0.478;	95%CI	
0.30-0.75;	P=0.001).	
	
A	single-centre	UK	study	of	130	patients	transplanted	for	malignancies	demonstrated	a	
trend	towards	a	negative	impact	of	double	HLA-DPB1	mismatching	on	overall	survival	in	
patients	 otherwise	 matched	 for	 10/10	 HLA	 loci	 (HLA-A,	 -B,	 -C,	 -DRB1,	 -DQB1).	 This	
finding	was	more	evident	in	patients	receiving	myeloablative	conditioning	compared	to	
those	receiving	RIC	(Burt	et	al.	2014).		
	
HLA-DPB1	mismatches	have	been	assigned	as	either	permissive	or	non-permissive	based	
on	observed	 immunogenicity	to	T-cell	epitopes	(Zino	et	al.,	2004	and	Crocchiolo	et	al.,	
2009b).	 The	 effect	 of	 dividing	 DPB1	mismatches	 into	 these	 two	 groups	 has	 provided	
evidence	of	DPB1	mismatching	impacting	on	survival.	In	a	study	of	621	unrelated	donor	
HPC	transplants,	recipients	with	permissive	DPB1	mismatches	had	a	significantly	higher	
2-year	 survival	 than	 those	 with	 non-permissive	 DPB1	 mismatches	 (55%	 versus	 39%,	
P=0.005).	 This	 improved	 survival	 was	 due	 to	 a	 decrease	 in	 NRM	 (Crocchiolo	 et	 al.,	
2009b).	Overall	non-permissive	DPB1	mismatches	 (unlike	earlier	studies	of	DPB1	allele	
mismatches)	were	not	associated	with	an	increase	in	aGVHD	and	concomitant	GVL.	
	
The	assignment	of	permissive	and	non-permissive	DPB1	mismatches	was	 included	 in	a	
large	 multicentre	 study	 (8539	 transplants)	 conducted	 by	 the	 International	
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Histocompatiblity	Workshop	Working	Group	in	HPC	transplantation	(Fleischhauer	et	al.,	
2012).	 Of	 the	 patients	 receiving	 a	 10/10	matched	 transplant	 (HLA-A,	 -B,	 -C,	 -DRB1,	 -
DQB1),	 HLA-DPB1	 non-permissive	 mismatches	 were	 associated	 with	 a	 significant	
increased	risk	of	overall	mortality	(HR	1.15,	95%	CI	1.05-1.25;	P=0.002);	NRM	(HR	1.28,	
1.14-1.42;	P<0.0001)	and	 in	 this	 study	an	association	was	observed	with	severe	GVHD	
(OR	1.31,	95%	CI	1.11-1.54;	P=0.001)	but	not	relapse	(HR	0.89,	95%	CI	0.77-1.02;	P=0.10)	
compared	 to	permissive	mismatches.	Although	differences	 in	outcome	were	observed	
between	 the	 DPB1	 matched	 and	 DPB1	 permissive	 mismatched	 patients,	 this	 did	 not	
affect	overall	mortality.	
	
A	 CIBMTR	 study	 of	 a	 patient	 cohort	 considered	 more	 contemporaneous	 based	 on,	
patient	disease,	transplant	conditioning	protocol	and	HPC	source	(peripheral	blood	stem	
cell,	 PBSC	 versus	 bone	marrow),	 has	 addressed	 the	 impact	 of	 DPB1	matching	 versus	
permissible	and	non-permissive	mismatches	(Pidala	et	al.,	2014).	An	increase	in	aGVHD	
grades	 II	 to	 IV	 and	 III	 to	 IV	 and	 a	 decrease	 risk	 of	 relapse	 was	 observed	 in	 patients	
receiving	 DPB1	 mismatched	 donors.	 Dividing	 the	 DPB1	 mismatched	 donors	 into	
permissive	 and	 non-permissive	mismatches	 identified	 the	 non-permissive	mismatches	
as	having	an	increase	in	transplant	related	mortality	and	an	increase	in	overall	mortality	
compared	 to	 both	 the	 permissive	 mismatched	 and	 the	 matched	 patients.	 The	 DPB1	
mismatching	outcome	was	only	significant	within	patients	receiving	an	8/8	and	a	10/10	
matched	donor.			
	
HLA-DPA1	is	significantly	less	polymorphic	than	HLA-DPB1	and	the	two	loci	are	in	linkage	
disequilibrium.	Analysis	of	the	role	of	HLA-DPA1	mismatches	had	no	effect	on	transplant	
outcome	observed	for	the	DPB1	permissive	and	non-permissive	mismatches	in	an	NMDP	
study	of	1281	10/10	matched	unrelated	donor	transplants	(Fleischhauer	et	al.,	2014)	
	
Although	 there	 are	 variations	 in	 the	 clinical	 outcomes	 for	 HLA-DPB1	 allele	 and	 non-
permissive	mismatched	 transplants,	 overall,	matching	 for	HLA-DPB1	 and	 avoidance	 of	
non-permissive	 mismatches	 is	 associated	 with	 better	 overall	 survival.	 	 Therefore,	
matching/mismatching	 at	 the	 HLA-DPB1	 locus	 should	 be	 considered	 on	 an	 individual	
basis,	taking	into	account	matching	at	other	loci	and	following	the	transplant	physician’s	
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evaluation	 of	 the	 patient’s	 transplant	 related	 risks.	 An	 online	 tool	 is	 available	 for	
assignment	 of	 permissive	 and	 non-permissive	 DPB1	 mismatches	 based	 on	 the	 T-cell	
epitope	analyses	performed	(Shaw	et	al.,	2013)	
	
Matching	for	HLA-DRB3,	-DRB4	and	-DRB5	(with	DQB1	and	DPB1)	
Further	 analysis	 of	 the	 NMDP	 dataset	 of	 3853	 unrelated	 donor	 transplants	 has	
demonstrated	that	whilst	not	significant	 in	 isolation,	mismatching	for	DRB3/4/5,	DQB1	
and	DPB1	(defined	as	“lesser	expressed	HLA	loci”,	LEL)	increased	the	risk	associated	with	
the	 presence	 of	 a	mismatch	 at	 HLA-A,	 -B,	 -C	 or	 -DRB1	 (Fernandez-Viña	 et	 al.,	 2013).	
Transplants	matched	for	7/8	HLA-A,	-B,	-C,	-DRB1	with	three	or	more	LEL	mismatches	in	
the	GvH	direction	had	a	higher	 risk	of	mortality	 and	 transplant	 related	mortality	 than	
7/8	 transplants	with	 0	 or	 1	 LEL	mismatches.	 Thus	HLA	 typing	donors	 and	patients	 for	
HLA-DRB3,	 -DRB4	 -DRB5,	 -DQB1	 and	 -DPB1	 is	 warranted	 when	 mismatched	 donor	
selection	is	occurring	in	order	to	minimise	the	number	of	mismatches	at	the	LEL.	
	
Direction	of	HLA	mismatch	
Donor	 and	 patient	 HLA	 mismatches	 may	 be	 bidirectional	 i.e.	 GVH	 and	 HVG	 or	
unidirectional	e.g.	GVH	(when	the	donor	 is	homozygous	for	a	particular	 locus)	or	HVG,	
when	 the	 patient	 is	 homozygous	 at	 a	 given	HLA	 locus.	 The	 effect	 of	 direction	 of	 HLA	
mismatch	has	been	investigated	within	a	cohort	of	2687	unrelated	donor	transplants	in	
patients	with	malignant	disease	(Hurley	et	al.,	2013).	 In	multivariate	analyses,	patients	
receiving	a	7/8	(HLA-A,	-B,	-C,	-DRB1)	matching	graft	with	unidirectional	GVH	mismatch	
and	patients	 receiving	 a	 7/8	bidirectional	mismatch	had	 significantly	worse	 transplant	
related	 mortality;	 overall	 survival	 and	 disease-free	 survival	 compared	 to	 patients	
receiving	 a	 8/8	matched	 transplant.	 This	worse	 transplant	outcome	 (compared	 to	8/8	
transplants)	 was	 not	 shared	 with	 patients	 receiving	 a	 7/8	 matching	 graft	 with	
unidirectional	HVG	mismatch.		
	
This	difference	in	outcome	observed	for	the	7/8	HVG	mismatches	is	likely	caused	by	the	
observed	 reduction	 in	 probability	 of	 acute	 GVHD	 observed	 in	 this	 group,	 which	 was	
significantly	 less	 than	 the	 7/8	 bidirectional	 mm	 and	 7/8	 GVH	mm	 (P=0.003)	 and	 not	
significantly	different	 from	 the	8/8	group.	No	differences	were	observed	between	 the	
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three	 7/8	 mismatched	 groups	 and	 the	 8/8	 matched	 transplants	 with	 other	 clinical	
outcomes	including	engraftment,	relapse	and	chronic	GVHD.	
These	findings	support	selection	of	a	7/8	HVG	mismatch	over	a	7/8	bidirectional	or	7/8	
GVH	mismatch	donor.		
	
This	study	did	not	confirm	previous	data	reported	by	the	Seattle	group	 in	2001	where	
transplants	 mismatched	 in	 the	 HVG	 direction	 were	 associated	 with	 lower	 neutrophil	
engraftment	and	secondary	graft	 failure.	However	 the	demographics	of	 the	 transplant	
group	 in	 this	 latter	 study	 differs	 in	 that	 the	 transplants	 were	 bone	marrow	 and	 HLA	
matching	was	not	completely	at	high	resolution	(Petersdorf	et	al.,	2001).	
	
HLA	typing	requirements	for	unrelated	donor	transplantation	
EFI	 standards	 v6.2	 recommend	 high	 resolution	 HLA-A,	 -B,	 -C	 and	 -DRB1	 typing	 to	 be	
performed	for	unrelated	progenitor	cell	transplantation	and	this	minimum	requirement	
is	 increasingly	enforced	by	the	unrelated	donor	registries	(Bray	et	al.,2008	Spellman	et	
al.,	2012	and	NMDP,	2015).	High	resolution	typing	of	the	patient	helps	to	determine	the	
likelihood	of	finding	a	potential	10/10	matched	donor.	The	optimal	number	of	donors	to	
select	for	further	HLA	typing	should	be	decided	on	a	patient	by	patient	basis	taking	into	
account	all	the	factors	that	can	influence	the	likelihood	of	finding	a	suitable	donor	and	
the	clinical	urgency.	Acceptable	levels	of	matching	and	mismatching	(i.e.	which	loci	must	
be	matched	and	which	may	be	mismatched)	must	be	determined	and	agreed	by	 local	
transplant	 policies.	 If	 the	 patient	 is	 to	 be	 entered	 onto	 a	 clinical	 trial	 that	 requires	 a	
10/10	matching	donor,	then	the	H&I	specialist	must	be	informed	to	avoid	wasting	time	
searching	for	mismatched	donors	if	there	are	no	fully	matched	donors	available	and	the	
transplant	 team	should	be	notified	as	 soon	as	 it	 is	 known	 that	a	 fully	matching	donor	
search	has	been	unsuccessful.	
	
Recommendations:	
1. The	patient	should	be	high	 resolution	typed	prior	 to	submitting	the	HLA	type	
for	an	unrelated	donor	search	(Grade	1A)	
2. A	10/10	high	resolution	HLA-A,	-B,	-C,	-DRB1	and	–DQB1	matched	unrelated	
PBSC	or	bone	marrow	donor	should	be	used	where	possible	(Grade	1A).	
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3. Where	a	10/10	matched	PBSC	or	bone	marrow	donor	is	not	available	a	single	
mismatch	at	HLA-A,	-B,	-C,	-DRB1	or	–DQB1	is	acceptable	(Grade	1A).	
4. Alternative	 progenitor	 cell	 donors	 (cord	 blood	 or	 haplo-identical)	 should	 be	
considered	early	in	the	donor	search	when	a	patient	is	unlikely	to	have	an	HLA	
matched	unrelated	donor	(Grade	1A).	
5. HLA-DRB3,	 -DRB4,	 -DRB5	 typing	 should	 be	 performed	 and,	when	 a	 choice	 of	
otherwise	 equally	 matched	 and	 appropriate	 (e.g.	 CMV	 status)	 donors	 is	
available,	mismatches	for	these	should	be	minimized	(Grade	2A).																																																																																			
6. For	 unrelated	 donor	 selection,	 HLA-DPB1	 typing	 should	 be	 performed	 and	
when	a	choice	of	otherwise	equally	matched	and	appropriate	(e.g.	CMV	status)	
donors	 is	 available,	 non-permissive	mismatches	 should	 be	minimised	 (Grade	
2C).	
7. For	mismatched	 related	 and	 unrelated	 donor	 selection,	HVG	mismatches	 are	
favoured	over	bi-directional	and	GVH	mismatches	(Grade	2C).	
8. All	 patients	 and	 unrelated	 donors	must	 have	 their	 HLA	 type	 confirmed	 on	 a	
second	sample	(Grade	1A).	
	
Selection	of	unrelated	umbilical	cord	blood	units	
	
Umbilical	cord	blood	is	an	alternative	source	of	HPCs	that	can	be	used	to	treat	patients	
with	both	malignant	and	non-malignant	disorders	 (reviewed	 in	Ballen	et	al.,	2013).	An	
early	study	undertaken	by	the	CIBMTR-Eurocord	showed	comparable	survival	outcomes	
comparing	 patients	 receiving	 HLA-identical	 cord	 blood	 transplants	 with	 patients	
receiving	 HLA-identical	 sibling	 donor	 transplants.	 This	 study	 highlighted	 delayed	
granulocyte	 and	 platelet	 engraftment	 in	 UCB	 transplant	 recipients	 but	 also	
demonstrated	a	reduction	in	both	acute	and	chronic	GVHD	(Rocha	et	al.,	2000).		
	
Similarly	 a	 comparison	 of	 unrelated	 HLA	 mismatched	 UCB	 transplants	 with	 matched	
unrelated	 adult	 donors	 transplants	 demonstrated	 recipients	 of	 the	 UCB	 transplants	
experienced	delayed	engraftment,	 less	acute	and	chronic	GVHD	with	a	 similar	 relapse	
rate,	overall	survival	(OS)	and	leukaemia	free	survival	(LFS),	(Rocha	et	al.,	2001).	
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The	use	of	UCB	was	initially	restricted	to	children	due	to	the	low	cell	doses	obtained	and	
poorer	 results	 obtained	 with	 adult	 recipients	 (Laughlin	 et	 al.,	 2001).	 However	 the	
selection	of	UCBs	with	higher	cell	doses	and	the	success	with	 infusion	of	 two	UCBs	 to	
adult	 recipients	 (double	 cord	blood	 transplants),	 together	with	 improved	 conditioning	
protocols	has	led	to	UCB	being	a	source	of	HPCs	for	both	children	and	adults	(Barker	et	
al.,	2003	and	Scaradavou	et	al.,	2013).	
	
The	reduced	incidence	and	severity	of	acute	and	chronic	GVHD	observed	following	UCB	
transplantation	has	allowed	the	use	of	mismatched	UCB	donors	which	would	exceed	the	
mismatches	accepted	in	related	or	unrelated	adult	donor	transplants.	This	has	led	to	the	
use	 of	 mismatched	 UCB	 donations	 to	 enable	 transplantation	 of	 patients	 that	 do	 not	
have	an	appropriately	matched	or	mismatched	adult	donor.	
	
In	an	analysis	of	1061	single	UCB	transplants	for	malignant	disease,	the	lowest	TRM	was	
observed	 in	recipients	of	0	mismatched	units	 (HLA-A,	 -B	 low/intermediate;	 -DRB1	high	
resolution)	 regardless	 of	 cell	 dose.	 For	 transplants	 performed	 with	 HLA	 mismatches,	
there	was	 a	 positive	 association	with	 survival	 outcomes	 for	 patients	with	 1	mismatch	
with	a	Total	Nucleated	cell	(TNC)	dose	≥	2.5	x107/kg	and	patients	with	2	mismatches	and	
a	TNC	dose	≥	5x107/kg,	with	no	difference	in	survival	outcomes	between	1	mismatched	
units	with	a	TNC	dose	2.5-4.9	x107/kg	and	2	mismatched	units	with	a	dose	of	≥	5x107.	
Therefore	the	greater	the	HLA	mismatch	between	UCB	donor	and	patient,	the	greater	is	
the	requirement	for	a	higher	TNC	dose	(Barker	et	al.,	2010).	
	
An	investigation	into	the	impact	of	HLA	allele	level	matching	(Eapen	et	al.,	2014)	found	
that	 independent	 to	 HLA	 matching,	 UCB	 TNC	 dose	 was	 the	 only	 other	 donor	 factor	
associated	with	NRM.	Transplants	performed	with	single	UCB	units	with	<3x107TNC/kg	
had	 NRM	 rates	 that	 were	 15-20%	 higher	 than	 transplants	 performed	 with	 UCB	 units	
with	a	higher	TNC.	
	
Thus	 the	 evidence	 supports	 HLA	 matching	 being	 critical	 above	 a	 minimum	 cell	 dose	
threshold.	HLA	matching	can	compensate	for	lower	TNC	dose	but	a	minimum	TNC	has	to	
be	achieved.	
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Role	of	HLA	matching	in	unrelated	umbilical	cord	blood	transplantation	
As	 successful	 outcomes	 can	 be	 achieved	 using	 mismatched	 UCB	 transplants,	 the	
requirement	for	high	/	allele	level	matching	between	UCB	unit	and	patient	has	not	been	
as	rigorous	with	matching	defined	using	HLA-A,	-B	low/intermediate	resolution	and	HLA-
DRB1	high	resolution	typing,	i.e.	6/6,	5/6,	4/6	etc.	
	
Matching	for	HLA-C	was	not	considered	originally	in	UCB	selection	algorithms,	however	
a	multicentre	 study	 of	 single	 UCB	 transplants	 identified	 a	 beneficial	 impact	 of	 HLA-C	
matching	as	HLA-C	mismatches	were	associated	with	an	increase	in	TRM.	The	negative	
impact	of	HLA-C	mismatching	was	observed	in	both	HLA-A,	-B	(intermediate	resolution),	
-DRB1	(high	resolution)	matched	and	mismatched	transplants	(Eapen	et	al.,	2011).	
	
The	 role	 of	 allele	 level	HLA	matching	 between	UCB	 and	 patient	was	 investigated	 in	 a	
cohort	 of	 1568	 recipients	 of	 single	 cord	 blood	 transplants	 for	 haematological	
malignancies	(Eapen	et	al.,	2014).		The	patients	were	predominantly	paediatric.	Analysis	
of	 allele	 level	 HLA	 matching	 demonstrated	 that	 only	 54%	 of	 patient/donor	 pairs	
considered	a	match	for	HLA-A,	-B	low,	-DRB1	high	resolution	were	matched	for	HLA-A,	-
B,	-C,	-DRB1	at	allele	level	resolution.		
	
HLA	allele	matching	 impacted	on	the	risk	of	NRM	with	pairs	mismatched	for	0,	1,	or	2	
alleles	 having	 reduced	 risk	 compared	 to	 transplants	 performed	 with	 3,	 4	 or	 5	 allele	
mismatches.	The	results	suggest	that	isolated	mismatches	at	HLA-A,	-C	or	-DRB1	but	not	
HLA-B	are	associated	with	a	threefold	increase	in	NRM	risk	suggesting	an	isolated	HLA-B	
mismatch	 may	 be	 better	 tolerated,	 although	 this	 finding	 has	 to	 be	 considered	 with	
caution	 as	 there	 were	 only	 31	 donor/patient	 pairs	 with	 isolated	 HLA-B	 mismatches	
within	 this	 transplant	 cohort.	 These	 results	 support	 HLA	 typing	 of	 UCB	 units	 to	
high/allele	level	resolution	for	accurate	selection	of	the	best	matching	unit.	Neutrophil	
recovery	was	lower	for	transplants	mismatched	for	3	or	more	alleles.	A	significant	effect	
of	HLA	allele	level	matching	on	the	incidence	of	aGVHD	II-IV	and	cGVHD	and	on	relapse	
was	 not	 observed,	 only	 UCB	 units	 mismatched	 for	 4	 or	 more	 alleles	 had	 increased	
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incidence	 of	 relapse.	 No	 significant	 association	 between	 HLA	 allele	 mismatching	 and	
overall	survival	for	transplants	performed	with	0-4	allele	mismatches	was	found.	
	
There	was	no	benefit	in	the	NRM	rates	by	increasing	the	TNC	to	>3x107/kg	in	transplants	
performed	with	0,	1,	2,	3	and	4	HLA	allele	mismatches.	Thus	when	 there	are	multiple	
UCB	units	available	with	TNC	≥3x107/kg,	 it	 is	not	necessary	to	select	 the	UCB	with	the	
largest	 TNC.	 Instead	 consideration	 should	 be	 made	 of	 the	 HLA	 matching	 available.	
Consideration	of	high	resolution	typing	together	with	cell	dose	has	demonstrated	that	
better	matching	UCB	units	may	be	selected	without	impeding	on	an	acceptable	cell	dose	
(Dahi	et	al.	2014).	
	
The	 impact	 of	 allele	 level	 mismatching	 on	 outcome	 in	 double	 cord	 transplants	 has	
recently	 been	 described	 in	 a	 single	 centre	 cohort	 of	 133	 patients	 transplanted	 for	
haematological	malignancies	 (Oran	et	al.	 2015).	 This	 study	 supports	matching	 at	 least	
5/8	HLA-A,	-B,	-C,	-DRB1	alleles	to	reduce	transplant	related	mortality.	
	
Direction	of	HLA	mismatch	
The	effect	of	direction	of	HLA	mismatch	was	investigated	in	a	cohort	of	1202	single	UCB	
unit	transplants.	Unidirectional	mismatches	were	identified	and	classified	as	either	GvH	
or	 HVG	 (rejection)	 mismatches.	 Engraftment	 was	 faster	 in	 patients	 with	 GVH	
unidirectional	mismatches	 compared	 to	patients	with	 single	bi-directional	mismatches	
HR=1.6,	 P=0.003).	 Other	 benefits	 to	 unidirectional	 mismatches	 included	 lower	 TRM,	
lower	 overall	 mortality	 and	 treatment	 failures.	 The	 HVG	 unidirectional	 mismatches	
exhibited	slower	engraftment,	higher	graft	failure	and	higher	relapse	rates.	
	
The	outcome	of	this	study	is	that	the	direction	of	the	mismatch	should	be	calculated	and	
priority	 should	 be	 given	 to	 unidirectional	 GVH	 mismatches	 over	 HVG	 unidirectional	
mismatches	(Stevens	et	al.,	2011)	
	
However,	these	findings	were	not	confirmed	in	a	Eurocord	study	of	1565	single	UCB	unit	
transplants	for	malignant	disease.	In	this	cohort,	one	or	two	HLA	mismatches	in	the	GVH	
or	HVG	direction	were	not	associated	with	NRM	and	survival	(Cunha	et	al.,	2014).		
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A	Japanese	study	of	2977	single	UCB	transplants	for	malignant	disease	did	not	find	any	
significant	 association	 with	 overall	 mortality	 for	 transplants	 performed	 with	
unidirectional	 mismatches	 in	 either	 GVH	 or	 HVG	 direction	 (Kanda	 et	 al.,	 2013).	 GVH	
mismatches	were	 associated	with	 a	 lower	 incidence	 of	 NRM	 for	 paediatric	 recipients	
only	which	were	also	associated	with	a	higher	incidence	of	relapse.	
	
The	 HLA	 data	 included	 in	 these	 three	 studies	 was	 not	 at	 high	 resolution	 therefore	
additional	mismatches	not	accounted	for	 in	the	analysis	are	likely.	HLA-C,	-DQ	and	-DP	
matching	was	 not	 considered.	 The	 role	 of	HLA	 alloantibodies	was	 not	 addressed.	 The	
impact	of	NIMA	matching	was	included	in	the	study	of	Stevens	et	al.,	(2011),	but	not	in	
the	others.	These	studies	are	also	complicated	as	multiple	mismatches	are	present	and	
not	 all	 mismatches	 (in	 the	 same	 direction)	 will	 impact	 the	 same	 biological	 effect.			
Further	work	is	required	to	elucidate	the	impact	of	unidirectional	mismatches.	
	
Impact	of	CD34+	cell	dose	
Although	the	TNC	count	is	used	at	the	time	of	unit	selection	as	a	measure	of	the	potency	
of	the	UCB	unit,	this	may	not	be	the	most	accurate	predictor	of	biological	engraftment.	
Prediction	of	engraftment	potential	of	transplanted	cord	blood	units	has	been	described	
based	on	precryopreservation	Colony	Forming	Unit	(CFU)	≥	50x103/kg,	(Migliaccio	et	al.,	
2000)	and	CD34+	cell	count	≥	1.5x105/kg	(Sanz	et	al.,	2010).	Post	thaw	counts	are	also	
valid	predictors,	however	these	are	only	available	after	the	UCB	unit	has	been	selected.		
	
A	 study	 of	 128	 double	UCB	 transplants	 performed	 in	 patients	with	malignant	 disease	
identified	 the	 cord	 blood	 bank	 precryopreservation	 CD34+	 cell	 dose	 of	 the	 dominant	
UCB	unit	as	the	only	independent	predictor	of	neutrophil	engraftment	(HR,	1.95;	95%CI:	
1.30-2.90;	 P=<0.001)	 (Purtill	 et	 al.,	 2014).	 The	 precryopreservation	 CD34+	 cell	 dose	
correlated	 with	 the	 transplant	 centres	 post	 thaw	 CD34+	 cell	 count,	 with	 better	
correlation	for:	i)	UCB	units	from	cord	blood	banks	that	were	FACT-Netcord		accredited	
compared	 to	 banks	 that	 did	 not	 have	 this	 accreditation,	 ii)	 UCB	 units	 banked	 during	
2005-2012,	compared	to		1997-2004.	
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Cryopreserved	 UCB	 units	 with	 volumes	 <24.5	 and	 >26.0	ml	 and	 UCB	 units	 from	 non-
accredited	banks	were	associated	with	 low	post	 thaw	CD34+	cell	 recovery	 (<65%)	and	
post	thaw	CD34+	cell	viability.	The	year	of	cryopreservation	and	processing	method	did	
not	impact	on	CD34+	cell	recovery	and	viability.	Compared	to	the	pre-cryopreservation	
TNC	count,	the	pre-cryopreservation	CD34+	cell	dose	correlated	better	with	post	thaw	
CD34+	 cell	 count	 and	 therefore	 this	 measurement	 was	 deemed	 a	 better	 overall	
predictor	of	successful	neutrophil	engraftment	with	an	arbitrary	CD34+	cell	threshold	of	
0.7x105/kg.	
	
The	UCB	unit	search	process	
A	 search	 for	 an	 UCB	 unit	 can	 be	 undertaken	 simultaneously	 with	 an	 adult	 unrelated	
donor	search.	This	is	essential	if	the	patient	has	a	rare	HLA	type	or	if	the	patient	requires	
a	speedy	transplant.	Within	the	UK	a	joint	Anthony	Nolan	and	BBMR	cord	blood	search	
report	 is	 produced	 when	 requested.	 International	 cord	 blood	 units	 are	 listed	 on	 the	
BMDW	website	 and	 a	 search	 report	 of	 these	will	 be	 provided	 by	 the	Anthony	Nolan.	
Additional	 information	on	UCB	units	stored	within	cord	blood	banks	in	the	USA	can	be	
obtained	via	searching	the	NMDP.	
	
A	 shortlist	 of	 up	 to	 10	 cords	 should	 be	 produced	 for	 each	 patient.	 These	 cords	 are	
selected	based	on	the	following	information	available	on	the	search	reports:	
	
1. TNC:	ensure	cords	shortlisted	meet	the	minimum	threshold	required	for	a	single	
(3x107/kg)	 and	 for	 a	 double	 UCB	 transplant	 (2	 x	 1.5x107/kg)	 as	 defined	 in	 the	
local	transplant	protocol	
2. HLA	match:	high	resolution	matching	for	HLA-A,	-B,	-C	and	-DRB1	at	a	mimimum	
should	be	considered	and	aim	 to	 select	UCB	with	≤	2	allele	mismatches	where	
possible	
3. CD34	cell	count:	indication	of	viability	of	cord	
4. Cord	blood	bank	accreditation	
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For	each	of	the	UCB	shortlisted,	a	request	should	be	made	to	the	cord	blood	bank	for	a	
detailed	 unit	 report.	 This	 will	 give	 additional	 information	 including	 viability	 testing	
performed;	method	for	volume	reduction,	volume	cryopreserved;	age	of	cord	etc.	
	
Confirmatory	HLA	typing	of	UCB	units	should	be	performed	according	to	FACT/NETCORD	
and	EFI	standards.	
	
Recommendations	
1. UCB	units	should	be	HLA	typed	to	high	resolution	HLA-A,	-B,	-C,	-DRB1,	-DQB1	
(Grade	1B	)	
2. Selection	of	UCB	units	 should	 follow	national	 consensus	 guidelines	published	
by	Hough	et	al.	(Grade	1A).	
	
	
	
HLA	alloantibodies	
	
Until	 recently	 the	 impact	 of	 HLA	 antibodies	 on	 HPC	 engraftment	 has	 been	 unclear.	
Opinion	was	 formed	 from	 contradictory	 case	 study	 reports	 in	 the	 literature	with	 few	
cases	 available	 for	 analysis	 because	of	 the	matching	 criteria	 inherent	 in	HLA	matched	
related	 and	unrelated	donor	 transplants.	 The	use	 of	HLA	mismatched	 cord	 blood	 and	
related	haploidentical	donors	has	 led	 to	more	 transplants	being	performed	where	 the	
patient	 has	 antibodies	 directed	 against	 HLA	 specificities	 present	 in	 the	 donor	 (donor	
specific	antibodies,	DSA).	Recent	studies	indicate	that	DSA	in	the	recipient	is	a	significant	
risk	factor	for	transplant	non-engraftment	(Ciurea	et	al.,	2011	and	Taniguchi	et	al.,	2012).		
	
In	 a	 Japanese	 study	 of	 374	 cord	 blood	 transplants,	 16.4%	 (41/250)	 of	 patients	 aged	
between	16	and	74	years	transplanted	for	malignancies	had	HLA	antibodies	(Takanashi	
et	al.,	2010).	Of	those	patients	eight	had	antibodies	against	HLA	antigens	present	in	the	
transplanted	cord	blood.	Engraftment	for	patients	with	HLA	antibodies	but	not	against	
antigens	present	in	the	transplanted	cord	blood	unit	was	93.6%	with	a	median	time	to	
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engraftment	of	21	days.	However	when	the	HLA	antibody	was	directed	at	donor	antigen,	
engraftment	fell	to	58%	(p=0.017)	with	a	median	time	to	engraftment	of	46	days.	
				
A	National	Marrow	Donor	Program	 study	 looking	 at	 failed	unrelated	 adult	 donor	HPC	
transplants,	found	that	the	presence	of	recipient	HLA	antibodies	reactive	to	donor	HLA	
antigens	was	associated	with	an	increased	risk	of	non-engraftment	(OR	22.8,	p=0.0002)	
(Spellman	et	al.,	2010).		
	
A	 further	American	study	of	73	double	cord	blood	 transplants	 revealed	 that	18	of	 the	
patients	 had	 donor	 specific	 antibodies	 (Cutler	 et	 al.,	 2011).	 Nine	 patients	 had	 DSA	
directed	 at	 the	 first	 infused	 CBU	 and	 two	 had	 DSA	 against	 the	 second	 infused	 CBU.	
Seven	patients	had	DSA	against	both	cord	units	 infused	and	four	patients	had	multiple	
DSA	antibodies	also	reactive	with	both	cords	infused.	The	study	links	important	clinical	
consequences	to	DSA.		
	
The	clinical	associated	complications	were:	
• An	increased	incidence	of	graft	failure	(5.5%	vs.	18.2%	vs.	57.1%	for	
		 none,	single	or	dual	DSA	positivity,	P=0.0001)	
• prolongation	of	the	time	to	neutrophil	engraftment	(21	vs.	29	days	
		 for	none	vs.	any	DSA,	P=0.04)		
• excess	100-day	mortality	or	relapse	(23.6%	vs.	36.4%	vs.	71.4%	for	
		 none,	single	or	dual	DSA	positivity,	P=0.01)		
• The	intensity	of	DSA	reactivity	was	correlated	with	graft	failure	
		 (median	of	mean	fluorescent	intensity	(MFI)	17,650	vs.	1,850,	P=0.039)	
	
Similar	 results	 emerged	 from	 a	 Eurocord	 registry	 analysis	 of	 UCB	 transplants	 (60%	
double	 cord)	 performed	 after	 RIC	 regimen	 (Ruggeri	 et	 al.,	 2013).	 Of	 294	 patients,	 62	
patients	(21%)	had	detectable	HLA	alloantibodies;	14	with	DSA	(7	double	cord	recipients	
and	 7	 single	 cord	 recipients).	 Cumulative	 Incidence	 of	 day	 60	 neutrophil	 engraftment	
was	reduced	in	those	patients	with	DSA	compared	to	patients	without	DSA	(44%	versus	
77%,	P=0.003).	In	multivariate	analysis,	the	pre-transplant	presence	of	DSA	was	the	only	
factor	that	independently	associated	with	neutrophil	recovery	(HR	1.69,	95%CI:	1.2-12.6;	
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P=0.002).	 	 There	 was	 also	 an	 association	 with	 the	 median	 MFI	 values,	 with	 those	
patients	engrafting	having	DSA	with	lower	MFI	values	compared	to	patients	that	did	not	
engraft.	Graft	failure	was	associated	with	a	higher	risk	of	TRM	and	lower	OS.	
		
These	 studies	 indicate	 that	 in	 HLA	 mismatched	 HPC	 transplants,	 HLA-DSA	 in	 the	
recipient	should	be	considered	as	a	significant	risk	factor	for	non-engraftment	and	that	
HLA	 antibody	 screening	 of	 patients	 prior	 to	 and	 following	 transplantation	 may	 be	 a	
useful	tool	to	follow	up	the	outcome	of	these	transplants.		
	
Recommendations		
1. HLA	alloantibody	testing	of	the	recipient	should	be	performed	at	the	time	of	donor	
search	 and	 should	 be	 repeated	 at	 the	 time	 of	 donor	work-up	 request	 if	 an	 HLA	
mismatched	donor	is	selected	(Grade	1A)	
2. The	 clinical	 team	must	 be	made	 aware	 of	 any	 HLA	 alloantibody	 incompatibility	
detected	in	the	recipient	(Grade	1A)		
3. When	 a	 choice	 of	 equally	 well	 matched	 donors	 is	 available,	 avoid	 selection	 of	
donors	against	which	the	patient	has	HLA	alloantibodies	(Grade	1A)	
4. HLA	alloantibody	testing	should	be	performed	in	cases	of	failed	engraftment	if	the	
donor	is	HLA	mismatched	(Grade	1B)		
	
Non-HLA	 factors	 to	 be	 considered	 for	 related	 and	 unrelated	 donor	
selection	
	
Cytomegalovirus	(CMV)	
CMV	 infection	 can	 cause	 significant	 complications	 post	 transplantation.	 CMV	 disease	
affects	 different	 organs	 including,	 lung	 (pneumonia);	 liver	 (hepatitis);	 gut	
(gastroenteritis);	 eye	 (retinitis)	 and	 the	 brain	 (encephalitis).	 Even	 with	 recent	
improvements	 in	 anti-viral	 prophylactic	 therapies,	 CMV	 seropositivity	 remains	
associated	 with	 an	 adverse	 prognosis	 and	 is	 still	 a	 major	 cause	 of	 morbidity	 and	
mortality	 in	 allogeneic	 SCT	 (reviewed	 in	 Ljungman	 2014a).	 CMV	 positivity	 can	 be	
transmitted	 from	 a	 positive	 donor	 to	 a	 negative	 patient	 and	 patients	 who	 are	 CMV	
positive	pre-transplant	are	susceptible	to	CMV	reactivation	post	transplant.	
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A	large	study	undertaken	by	EBMT	of	16,628	allo-transplanted	acute	leukaemia	patients	
(Schmidt-Hieber	 et	 al.,	 2013)	 reported	 that	 donor	 or	 recipient	 CMV	 seropositivity	
(versus	 donor	 and	 recipient	 CMV	 seronegativity)	 was	 associated	 with	 a	 significant	
decrease	in	leukaemia	free	survival	and	overall	survival	with	an	increase	in	NRM	and	a	
small	 increase	 in	 relapse	 incidence.	The	negative	 impact	on	disease	 free	survival	 (DFS)	
and	 OS	 held	 up	 in	 multivariate	 analyses.	 OS	 was	 reduced	 in	 ALL	 (46%	 for	 CMV	
seropositive	donor	and/or	patient	versus	55%	for	CMV	seronegative	donor	and	patient)	
compared	with	AML	 (52%	 for	CMV	seropositive	donor	or	patient	versus	56%	 for	CMV	
seronegative	donor	and	patient).	This	was	despite	the	use	of	strategies	for	prophylaxis,	
monitoring,	and	pre-emptive	treatment	of	CMV.	There	was	no	effect	of	CMV	status	on	
acute	and	chronic	GVHD.	
	
The	negative	effect	of	CMV	seronegative	patients	receiving	CMV	seropositive	donations	
from	unrelated	donors	was	confirmed	in	a	second	EBMT	study	of	transplants	performed	
in	20,193	CMV	seronegative	patients.	However	no	effect	was	seen	in	patients	receiving	
transplants	from	related	donors	(Ljungman	et	al.,	2014b).		
	
Two	smaller	studies	of	patients	transplanted	for	B-cell	lymphoma	(Mariotti	et	al.,	2014)	
and	myeloma	(El-Cheikh	et	al.,	2013)	did	not	identify	any	impact	of	CMV	serostatus	on	
outcome.		
	
The	 impact	 of	multiple	 donor	 factors	 including	 CMV	on	 survival	was	 investigated	 in	 a	
multi-centre	 study	 of	 1271	 UK	 patients	 transplanted	 with	 an	 unrelated	 donor	 for	
malignant	disease	(Shaw	et	al.,	2014).		Patients	who	were	CMV	seropositive	at	the	time	
of	transplant	had	a	reduced	median	survival	(1.7	years)	compared	to	CMV	seronegative	
patients	 (2.5	 years,	 p=0.013).	 The	 donor	 and	 patient	 CMV	matching	 status	 impacted	
differential	survivals	of	2.8,	2.2,	1.5	and	1.1	years	in	the	categories	of	neg/neg,	pos/pos,	
neg/pos	and	pos/neg	(p=0.001).	A	relationship	between	HLA	matching	and	CMV	status	
on	outcome	was	not	observed	for	CMV	seronegative	patients	regardless	of	whether	the	
donor	was	CMV	matched	or	mismatched	(p=0.061),	either	in	the	10/10	(p=0.61)	or	9/10	
matched	setting	 (p=0.13).	However	there	was	a	difference	 in	median	survival	 for	CMV	
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seropositive	 patients	 with	 a	 10/10	 HLA	 matched	 donor	 at	 1.8	 years	 with	 a	 CMV	
seronegative	donor	and	2.4	years	with	a	seropositive	donor	(p=0.23).	When	the	donor	
was	 a	 9/10	 HLA	match,	 the	 median	 survival	 was	 0.7	 years	 with	 a	 CMV	 seronegative	
donor	compared	to	2.2	years	with	a	CMV	seropositive	donor	(p=0.004).	The	difference	
in	 survival	 was	 attributed	 to	 an	 increase	 in	 GVHD	 and	 the	 morbidity	 and	 mortality	
associated	with	 recurrent	CMV	reactivations.	This	 study	supports	better	outcomes	are	
achieved	when	donor	and	patient	are	matched	for	CMV	status.	
	
CMV	 seropositive	 patients	 receiving	 transplants	 from	 CMV	 seropositive	 donors	 have	
been	 reported	 to	 have	 better	 survival	 and	 reduced	 TRM	 compared	 to	 seropositive	
patients	receiving	seronegative	donations	(Ljungman	et	al.,	2003).	The	study	of	Schmidt-
Hieber	et	al.,	also	demonstrated	that	CMV	seropositive	recipients	of	a	CMV	seropositive	
graft	had	a	significantly	(P=.04)	better	OS	compared	to	CMV	seropositive	recipients	of	a	
CMV	seronegative	graft,	with	no	difference	in	LFS	observed	(P=0.24)	(Schmidt-Hieber	et	
al.,	2013).		
	
Analysis	 of	 29,349	 CMV	 seropositive	 transplant	 recipients	 identified	 within	 the	 EBMT	
registry	 found	 no	 effect	 of	 donor	 CMV	 status	 on	 outcome	 for	 transplants	 performed	
with	 a	matched	 or	mismatched	 family	 donor	 (Ljungman	 et	 al.,	 2014b).	 An	 effect	was	
observed	 for	 CMV	 seropositive	 patients	 receiving	 transplants	 from	 unrelated	 donors	
with	lower	relapse	mortality	observed	albeit	at	borderline	significance	(HR	0.94;	P=.05)	
when	 a	 CMV	 seropositive	 donor	 was	 used.	 For	 patients	 receiving	 myeloablative	
conditioning	 better	 overall	 survival;	 lower	 NRM	 and	 improved	 relapse-free	 survival	
outcomes	were	observed	when	the	donors	were	CMV	seropositive.	Similar	effects	were	
not	observed	for	patients	transplanted	with	RIC.		The	retention	of	host	CMV	specific	T-
cell	 function	 in	 patients	 receiving	 RIC	 is	 an	 explanation	 for	 the	 lack	 of	 an	 association	
observed	(Ljungman	et	al.,	2014b).			
	
The	British	Committee	 for	Standards	 in	Haematology,	 the	British	Society	of	Blood	and	
Marrow	 Transplantation	 and	 the	 UK	 Virology	 Network	 guideline	 for	 Management	 of	
cytomegalovirus	infection	in	haematopoietic	stem	cell	transplantation	recommend	CMV	
matching	between	patient	and	donor	(Emery	et	al.,	2013).	
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ABO	blood	group	incompatibility	
ABO	 incompatibility	 (ABOi)	 between	 patient	 and	 donor	 is	 a	 common	 feature	 of	 HPC	
transplantation.	 The	 ABOi	 can	 be	major,	minor	 or	 bidirectional	 (Table	 1).	Major	 ABOi	
transplants,	 in	 particular	 for	 blood	 group	 O	 patients,	 can	 cause	 delayed	 red	 cell	
engraftment,	 and	 infrequently	 pure	 red	 cell	 aplasia	 (PRCA).	 Reduced-toxicity	 regimes	
such	 as	 low	 intensity	 conditioning	 and	 graft	 versus	 host	 prophylactics	 are	 associated	
with	extended	host	isohaemaglutinin	production	and	PRCA	(Bolan	et	al.,	2001).	
	
Major	 and	 minor	 ABO	 incompatibilities	 do	 not	 have	 a	 significant	 effect	 on	 overall	
survival	and	incidence	of	GVHD	(reviewed	in	Booth	et	al.,	2013)	and	do	not	constitute	a	
major	 contraindication	 to	 donor	 selection.	 	 However	 there	 are	 several	 single-centre	
studies	that	indicate	ABOi	having	an	impact	on	clinical	outcome.	
	
Recipients	 of	major	 and	minor	 ABOi	 RIC	 transplants	 are	 dependent	 on	 red	 blood	 cell	
transfusions	for	longer	compared	to	ABO	compatible	RIC	transplants	(Watz	et	al.,	2014).	
Patients	receiving	major	ABOi	RIC	transplants	who	then	developed	persistent	recipient	
type	ABO	 (PRABO)	antibodies	had	a	poorer	overall	 survival	 (17%	v	73%,	P=0.002)	and	
transplant	related	mortality	(50%	v	21%,	P=0.03)	compared	to	patients	receiving	major	
ABO	incompatible	RIC	transplants	without	PRABO	(Watz	et	al.,	2014).	
	
An	investigation	into	red	cell	aplasia,	for	transplants	performed	between	2007	and	2008,	
identified	 27%	 of	 patients	 received	 major	 ABOi	 transplants	 and	 7.5%	 of	 these	 major	
ABOi	transplanted	patients	developed	PRCA	(Aung	et	al.,	2013).	Chimerism	studies	for	T-
cell	 and	myeloid	cell	 lineage	and	 time	 to	engraftment	 for	neutrophil	 and	platelets	did	
not	differ	significantly	for	the	major	ABOi	patients	that	did,	and	did	not	develop	PRCA.	
All	 patients	 with	 PRCA	 required	 red	 cell	 transfusion	 support	 for	 several	 months	 and	
suffered	 from	 significant	 iron	 overload.	 These	 complications	 can	 be	 reduced	 where	
major	ABO	mismatches	are	avoided	in	donor	selection.	
	
Therefore	in	selection	of	HPC	donors,	avoidance	of	major	ABOi	 is	preferred,	but	 in	the	
absence	of	a	minor	ABOi	or	ABO	compatible	donor,	major	ABO	incompatibilities	can	be	
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selected.	 	When	a	blood	group	O	patient	 is	 being	 considered	 for	ABOi	 transplant	 it	 is	
useful	to	determine	the	patient’s	anti-A	and	anti-B	titres	as	this	may	help	the	selection	
when	there	is	a	choice	of	ABOi	donors.	
	
Donor	Sex	
Using	 a	male	donor	has	been	 reported	 in	 some	 studies	 as	 having	 a	 positive	 effect	 on	
long	 term	 survival	 regardless	 of	 the	 sex	 of	 the	 recipient	 (Gustafsson	 et	 al.,	 2004	 and	
Pond	et	al.,	2006)	but	not	 in	others	 (Lee	et	al.,	2007).	Regardless,	donor	sex	selection	
priority	 is	usually	given	to	male	donors	due	of	 their	usually	 larger	size	associated	with	
higher	HPC	 counts	 obtained	 and	 also	 because	 of	 the	 increase	 in	GVHD	 that	 has	 been	
reported	with	female	multiparous	donors	(Kollman	et	al.,	2001).	A	recent	German	study	
of	2,646	transplants	performed	in	patients	with	haematological	malignancies	found	that	
transplants	 performed	 with	 international	 donors	 had	 a	 worse	 outcome	 compared	 to	
transplants	 with	 national	 donors	 and	 male	 patients	 transplanted	 with	 female	
international	donors	showed	an	even	higher	hazard	ratio	 in	analysis	of	OS	(HR	1.51,	CI	
1.18-1.92,	p<0.001)	than	other	sex	matched	groups	(Fürst	et	al.,	2013).	
	
In	contrast,	a	multi-centre	analysis	of	the	effect	of	donor	characteristics	on	the	outcome	
of	 709	 RIC	 transplants	 (Passweg	 et	 al.,	 2011)	 demonstrated	 no	 association	 between	
donor	age,	parity	and	sex	matching	with	 transplant	outcome,	with	only	HLA	matching	
being	predictive	for	survival.			
	
An	 investigation	 into	 the	 impact	 of	 cord	 blood	 donor	 sex	 compatibility	 has	
demonstrated	 no	 impact	 on	 survival	 in	 adults	 with	 haematological	 malignancies	
receiving	a	myeloablative	single	unit	cord	blood	transplant.	However,	a	higher	incidence	
of	chronic	GVHD	(HR	2.97,	P=0.02)	was	observed	in	male	recipients	of	female	cord	blood	
donors	 and	 a	 lower	 incidence	 of	 platelet	 engraftment	 (HR	 0.56,	 P=0.02)	 in	 female	
recipients	with	male	 cord	 blood	 donors	 (Konuma	et	 al.,	 2014).	 These	 findings	 require	
confirmation	in	further	studies.	
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Donor	Age	
In	 a	 2001	NMDP	 study	of	 6,978	unrelated	donor	 transplants	performed	 from	1987	 to	
1999	 recipients	 receiving	 transplants	 from	younger	 aged	donors	were	associated	with	
lower	 levels	 of	 aGvHD	 III-IV	 (30%	 18-30	 years;	 34%	 31-45	 years	 and	 34%	 >45	 years,	
p=0.005)	and	cGvHD	(44%	18-30	years;	48%	31-45	years	and	49%	>45	years,	p=0.02)	and	
improved	5	year	overall	survival	(33%	18-30	years;	29%	31-45	years	and	25%	>45	years,	
p=0.0002)	 (Kollman	 et	 al.,	 2001).	 The	 transplants	 included	 in	 this	 study	 were	 not	 all	
matched	 for	 high	 resolution	 HLA	 typing	 and	 included	 both	 HLA	 matched	 and	
mismatched	 donors.	 However	 another	 large	NMDP	 study	 of	 3,,857	 transplants	where	
high	resolution	matching	was	included	was	unable	to	confirm	this	donor	age	effect	(Lee	
et	al.,	2007).	
	
A	 recent	 study	 of	 donor	 age	 in	 both	matched	 sibling	 transplants	 and	 high	 resolution	
matched	 unrelated	 transplants	 found	 no	 significant	 difference	 in	 overall	 survival	 in	
recipients	 of	 transplants	 from	matched	 unrelated	 donors	 in	 three	 age	 groups:	 	 19-29	
years	(n=254)	vs.	30-39	years	(n=306)	vs.	40-49	years	(n=194);	p=0.5	(Alousi	et	al.,		2013).	
This	 study	 only	 included	 patients	 over	 the	 age	 of	 50	 which	 may	 have	 impacted	 the	
results	obtained.	
	
A	 CIBMTR	 study	 (GS08-01)	 of	 6,349	 transplants	 examining	 the	 effect	 of	 donor	
characteristics	 on	 GVHD	 and	 survival	 following	 unrelated	 donor	 HPC	 transplantation	
identified:	 donor	 age;	 high	 resolution	 HLA	 matching	 and	 blood	 group	 matching	
associated	with	overall	survival.	Specifically	patients	transplanted	from	older	donors	had	
lower	overall	 survival	at	 five	years	compared	 to	younger	donors:	Donors	aged	33	 -	50	
years	(HR	1.13,	P=0.0004)	and	>50	years	(HR	1.29,	P<0.0001)	compared	to	donors	aged	
18	-	32	years	(Kollman	et	al.,	2013).		
	
NK	cell	receptors	
NK	cells	participate	in	the	defence	against	infection,	malignancy	and	allo-antigens.	These	
reactions	 are	 mediated	 by	 receptors	 on	 the	 NK	 cells	 and	 ligands	 on	 the	 target	 cells	
including	 Killer-cell	 Immunoglobulin-like	 Receptors	 (KIR)	 and	 HLA	 respectively.	
Mismatching	for	HLA	proteins	that	interact	with	different	KIR	such	as	HLA-C,	can	initiate	
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GVH	 NK	 cell	 mediated	 alloreactions.	 Post	 transplantation,	 NK	 cells	 will	 be	 generated	
with	 the	KIR	 repertoire	of	 the	donor.	 Included	within	 this	NK	cell	population	will	exist	
alloreactive	 NK	 cells	 defined	 by	 their	 killing	 ability	 not	 being	 inhibited	 by	 any	
mismatched	HLA	proteins	 expressed	 by	 host	 cells	 including	 dendritic	 cells,	 T-cells	 and	
leukaemic	 cells	 resulting	 in	 a	 reduction	 in	 GVHD;	 prevention	 of	 graft	 rejection	 and	
destruction	of	residual	leukaemic	cells	respectively.		
The	latter	graft	versus	leukaemia	(GVL)	effect	could	be	enhanced	if	donors	are	selected	
to	encourage	NK	cell	mediated	alloreactivity.	This	was	first	demonstrated	in	the	study	of	
Ruggeri	 et	 al.	 (2002)	 who	 demonstrated	 improved	 survival	 attributed	 to	 decreased	
relapse,	GVHD	and	 rejection	 in	AML	patients	 receiving	KIR	 ligand	 (HLA-C)	mismatched	
transplants.	The	mechanism	for	this	effect	was	attributed	to	the	donor	possessing	allo-
reactive	 NK	 cells	 that	 were	 not	 inhibited	 by	 the	 patient’s	 mismatched	 HLA-C	 allele.	
However	the	results	observed	in	this	study	have	not	been	extensively	reproduced	with	
some	 studies	 reporting	 worse	 overall	 survival	 (Leung	 2011).	 This	 is	 attributed	 to	
heterogeneity	 in	 the	 patient	 and	 donor	 demographics;	 the	 diagnoses,	 with	 AML	
recognised	as	being	the	main	disease	affected	by	NK	cell	alloreactivity;	and	also	the	T-
cell	content	of	the	transplanted	graft.	Additionally,	analysis	of	the	KIR	ligand	mismatch	
alone	does	not	account	for	the	variability	of	KIR	proteins	caused	by	differences	in	gene	
content	and	polymorphisms	affecting	expression	and	functionality.		
KIR	genes	are	 located	on	chromosome	19,	and	as	such	are	 inherited	 independently	of	
HLA	 genes.	 Two	 groups	 of	 KIR	 haplotypes	 have	 been	 described.	 Haplotype	 ‘KIR	 A’	
possesses	one	activating	gene	whereas	haplotype	 ‘KIR	B’	possesses	multiple	activating	
genes	and	as	such	KIR	B	is	considered	to	effect	greater	alloreactivity	than	KIR	A.	Analysis	
of	the	 impact	of	KIR	haplotypes	on	transplant	outcome	has	shown	that	transplants	(T-
replete)	with	donors	possessing	at	 least	one	KIR	B	haplotype	had	a	 three	year	overall	
survival	 that	 was	 significantly	 higher	 that	 transplants	 performed	 with	 donors	 that	
possessed	 two	 KIR	 A	 haplotypes	 (31%	 v	 20%,	 p=0.007)	 (Cooley	 et	 al.,	 2009).	 Further	
studies	have	associated	the	presence	of	KIR	B	in	the	donor	with	relapse	protection	and	
improved	 survival	 for	 patients	 with	 AML	 but	 not	 ALL,	 with	 homozygosity	 for	 KIR	 B	
haplotype	 centromeric	motifs	 having	 the	 strongest	 independent	 effect	 (Cooley	 et	 al.,	
2010).	
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Further	study	(Venstrom	et	al.,	2012)	of	a	CIBMTR	cohort	of	patients	with	both	AML	and	
ALL	 demonstrated	 decreased	 rate	 of	 relapse	 for	 AML	 but	 not	 ALL	 patients	 when	 the	
donor	 possessed	 the	 KIR	 B	 haplotype	 gene	 KIR2DS1	 in	 association	 with	 the	 donor	
possessing	 one	 or	 two	HLA-C	 allotypes	with	 the	 C1	 epitope	 (not	 ligands	 for	KIR2DS1)	
compared	 to	 donors	 that	 were	 HLA-C	 homozygous	 for	 the	 C2	 epitope	 (ligands	 for	
KIR2DS1)	 or	 negative	 for	 KIR2DS1.	 Mismatching	 for	 HLA-C	 in	 the	 absence	 of	 donor	
KIR2DS1	did	not	impact	on	relapse.	Individuals	that	are	KIR2DS1	and	HLA-C	C2	epitope	
homozygotes	have	previously	been	shown	to	be	hyporesponsive	to	target	cells	due	to	a	
tolerogenic	 effect	 of	 the	 interaction	 between	 KIR2DS1	 and	 its	 self	 ligand	 (Sun	 et	 al.,	
2008	and	Tripathy	et	al.,	2008)	supporting	an	alloreactive	response	mediated	by	NK	cells	
expressing	 KIR2DS1	 and	 HLA-C	 with	 the	 C1	 epitope.	 The	 presence	 of	 HLA-C	 with	 C1	
epitope	 within	 the	 patient	 also	 associated	 with	 reduced	 relapse	 when	 the	 donor	
expressed	KIR2DS1.	This	was	not	observed	when	the	patient	was	homozygous	for	HLA-C	
with	 C2	 epitope	 (Venstrom	 et	 al.,	 2012).	 Therefore	 genotyping	 donors	 for	 KIR2DS1	 is	
required	to	assess	this	effect	on	outcome.	
The	impact	of	KIR	B	haplotype	specific	motifs,	as	defined	by	variable	gene	content	at	the	
centromeric	and	telomeric	ends	of	KIR	B	haplotypes	was	investigated	in	a	cohort	of	1532	
T-cell	 replete	 transplants	 for	 AML	 (Cooley	 et	 al.,	 2014).	 56%	 of	 the	 transplants	 were	
matched	for	HLA-A,	-B,	-C,	-DRB1	and	-DQB1	with	the	remainder	having	1,	2,	3	or	more	
mismatches.	Confirming	previous	studies,	transplants	performed	with	donors	possessing	
two	or	more	KIR	B	motifs	experienced	an	 increase	 in	LFS	and	protection	from	relapse,	
compared	to	transplants	performed	with	donors	possessing	0	or	1	B	motif.	
Patients	 possessing	 one	 or	 two	 HLA-C	 allotypes	with	 the	 C1	 epitope	were	 associated	
with	 improved	LFS	attributed	to	a	reduction	 in	relapse	when	the	donor	possesses	2	or	
more	KIR	B	motifs,	but	not	when	the	donor	possessed	1	or	0	B	motifs.	This	effect	was	
most	 significant	 for	 the	 HLA-C	 mismatched	 transplants	 with	 enhanced	 LFS	 (RR	 0.57	
[0.40-0.79],	p=0.001)	and	reduced	relapse	(RR	0.54	[0.33-0.88],	p=0.013).	Comparison	of	
the	HLA-C	mismatches,	within	this	subset	of	transplants,	did	not	show	a	benefit	for	KIR	
ligand	 (C1	 and	 C2	 epitope)	 mismatching.	 This	 data	 supports	 a	 benefit	 of	 HLA-C	
mismatching,	 in	terms	of	 improved	LFS	due	to	a	reduction	 in	relapse,	when	the	donor	
possesses	2	or	more	KIR	B	motifs	and	the	patient	possesses	at	least	one	HLA-C	allotype	
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with	the	C1	epitope.	In	contrast	no	significant	associations	with	donor	KIR	was	observed	
for	 the	 Bw4	 and	 C2	 epitopes	 when	 present	 in	 the	 patient	 or	 the	 Bw4,	 C1	 and	 C2	
epitopes	present	in	the	donor.		
Although	 the	 data	 supporting	 donor	 KIR	 B	 haplotype	 and/or	 B	 motif	 together	 with	
patient	KIR	ligand	HLA-C	epitope	having	an	impact	on	transplant	outcome	is	impressive,	
there	 currently	 is	no	 large	 scale	 study	described	with	patients	 transplanted	 in	 a	 T-cell	
deplete	protocol	receiving	predominantly	PBSC	donations	to	verify	the	data	described,	
that	has	been	procured	from	predominantly	north	American	cohorts	with	T-cell	replete	
protocols	and	bone	marrow	donations.		
Recommendations	
1. The	 guideline	 published	 by	 Emery	 et	 al.,	2013	 recommending	 CMV	matching	
between	patient	and	donor	should	be	followed	(Grade	1A)	
2. Major	ABO	incompatibilities	should	be	avoided	when	there	is	a	choice	of	HLA	
and	CMV	matched	donors	(Grade	1A)	
3. Male	 donors	 should	 be	 preferentially	 chosen	where	 the	 patient	 has	multiple	
HLA,	CMV	and	ABO	matched	donors	(Grade	1C).	
4. Younger	donors	should	be	preferentially	selected	(Grade	1B)	
 
 
Tumour	specific	mutations	
	
The	improvement	and	wide	scale	application	of	high	resolution	HLA	typing	methods	has	
led	 to	 a	 significant	 increase	 in	 the	 number	 of	 mutations	 identified	 when	 HLA	 typing	
patients	using	DNA	extracted	from	peripheral	blood.	These	mutations	can	be	attributed	
to	a	novel	HLA	allele	expressed	in	all	tissues	or	could	be	specific	to	the	patient’s	tumour	
(Mrazek	et	al.,	2014).	If	discovered,	effort	must	be	made	via	HLA	typing	of	relatives	and	
HLA	typing	of	DNA	extracted	from	patient	tissue	not	affected	by	disease	(e.g.	skin	plug)	
to	determine	whether	 the	allele	 is	novel	or	 tumour	 specific.	Only	novel	 alleles	will	 be	
assigned	an	official	HLA	allele	name	(Marsh	et	al.,	2010	and	Robinson	et	al.,	2015).	
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The	 expression	 of	 HLA	 proteins	 can	 be	 reduced	 within	 tumours	 due	 to	 deletion	 or	
mutations	within	genes	encoding	HLA	proteins.	 Loss	of	heterozygosity	 at	HLA	 loci	 can	
also	occur.	Care	must	be	taken	when	patients	are	HLA	typed	from	DNA	extracted	from	
peripheral	blood	with	a	high	frequency	of	 tumour	cells	 in	circulation.	Homozygosity	at	
HLA	loci	must	be	confirmed	via	family	studies	or	repeat	HLA	testing	when	the	patient	is	
in	remission	or	by	testing	DNA	extracted	from	a	non-diseased	cells	such	as	buccal	swab	
or	skin	plug.		
	
Recommendation	
Homozygosity	 and	 novel	 HLA	 alleles	 identified	 within	 DNA	 extracted	 from	 patients	
with	 a	 high	 frequency	 of	 circulating	 tumour	 cells	 should	 be	 confirmed	 by	 family	
studies	or	using	DNA	extracted	from	non-diseased	cells	(Grade	2A)	
	
Graft	Identification	Advisory	Service	(GIAS)	
	
The	provision	of	a	professional	GIAS	to	a	transplant	centre	requires	trained	staff	able	to	
undertake	both	 straight-forward	and	 complex	donor	 selection.	GIAS	may	be	delivered	
from	an	H&I	laboratory	supporting	the	transplant	centre;	from	a	donor	registry	or	from	
within	 the	 transplant	 team.	 Key	 to	 the	 successful	 selection	 of	 optimum	 donors	 from	
related	 and	 unrelated	 sources	 is	 expert	 knowledge	 of	 the	 HLA	 system	 including:	
polymorphism,	 linkage	 disequilibrium,	 impact	 of	 recombination,	 ethnic	 variation	 and	
HLA	 serology.	 A	 GIAS	 service	 must	 be	 directed	 by	 a	 consultant	 grade	 RCPath	 Fellow	
trained	in	H&I,	with	adequate	cover	provide	during	absences.	This	may	be	achieved	via	
network	arrangements	with	other	organisations.		
	
H&I	 scientists	 who	 have	 completed	 the	 British	 Society	 for	 Histocompatibility	 and	
Immunogenetics	 (BSHI)	 diploma	 and	 are	 Health	 and	 Care	 Professions	 Council	 (HCPC)	
registered	 will	 have	 achieved	 an	 adequate	 level	 of	 education	 to	 enable	 active	
participation	 within	 a	 GIAS	 structure.	 Other	 “non	 H&I	 laboratory”	 training	 pathways	
such	as	that	provided	by	the	WMDA	should	be	documented	for	members	of	a	GIAS	team.	
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Regular	interactions	between	the	GIAS	and	transplant	teams	must	take	place	via	multi-
disciplinary	 team	 meetings,	 to	 ensure	 the	 needs	 of	 individual	 patients	 are	 being	
delivered	according	to	local,	national	and	international	transplant	protocols.	
	
All	GIAS	team	members	must	participate	in	continual	professional	development	(CPD)	to	
ensure	maintenance	of	current	knowledge	and	to	be	aware	of	future	developments.		
	
Recommendation	
Individuals	 actively	 involved	 in	 the	 provision	 of	 a	 donor	 selection	 service	 should	
undertake	CPD	and	the	service	should	be	directed	by	a	RCPath	Fellow	and	Consultant	
in	H&I	(Grade	1A)	
	
Useful	websites	
	
Guidance	and	tools	to	assist	in	donor	selection	and	allele	frequencies	are	freely	
available	at	the	following	sites:	
	
NMDP	bioinformatics	resources	https://bioinformatics.bethematchclinical.org/	 includes	
tools	 such	 as	 haplostats	 for	 aiding	 haplotype	 prediction	 and	 an	 on	 line	 tool	 for	
deciphering	NMDP	codes.	Tables	with	haplotype	frequencies	in	different	ethnic	groups	
are	also	available.	
	
Bone	Marrow	Donors	Worldwide,	 http://bmdw.org,	 is	 the	 continuing	 effort	 to	 collect	
the	 HLA	 phenotypes	 and	 other	 relevant	 data	 of	 volunteer	 stem	 cell	 donors	 and	 cord	
blood	units,	and	is	responsible	for	the	co-ordination	of	their	worldwide	distribution.		
	
HLA	Nomenclature	information:	http://hla.alleles.org	
Houses	up	to	date	HLA	nomenclature	including	easy	to	use	tables	of	alleles	and	lists	
of	alleles	in	G	and	P	groups.	
	
IPD-IMGT/HLA	 Database	 permits	 access	 to	 HLA	 DNA	 and	 protein	 sequences,	
http://www.ebi.ac.uk/ipd/imgt/hla/	 and	 includes	 the	 official	 sequences	 for	 the	 WHO	
Nomenclature	Committee	For	Factors	of	the	HLA	System.	The	IPD-IMGT/HLA	Database	is	
part	of	the	Immuno	Polymorphism	Database	(IPD).		
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Table	1	
Types	of	donor	–	recipient	ABO	incompatibilities	
Mismatch	type	 ABO	blood	type	
Recipient	 Donor	
Major	 O	 A,	B,	AB	
Major	 A	 AB	
Major	 B	 AB	
Minor	 A	 O	
Minor	 B	 O	
Minor	 AB	 O,	A,	B	
Bidirectional	 A	 B	
Bidirectional	 B	 A	
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Figure	legends	
	
Figure	1.		
Diagram	 representing	 the	 interaction	 with	 between	 different	 levels	 of	 HLA	 typing	
resolution	and	their	nomenclature.	Modified	from	Nunes	et	al.,	2011.		
	
Figure	2	
a	
High	resolution	typing	for	HLA-A,	-B	and	–DRB1	identifies	both	sibling	1	and	sibling	2	as	
having	the	same	HLA	type	as	the	patient.	The	father	appears	homozygous	for	all	HLA	loci	
tested.	
	
b	
Extended	 typing	 for	 HLA-C	 and	 DQB1	 identifies	 sibling	 1	 as	 being	 mismatched.	 The	
father	is	heterozygous	for	HLA-C	and	DQB1.	
	
Figure	3	
a	
Low	resolution	typing	at	five	HLA	loci	identifies	both	sibling	1	and	2	as	having	the	same	
HLA	type	
	
b	
HLA	allele	 level	 typing	 identifies	 the	 father	 as	being	heterozygous	 and	 sibling	1	 and	2	
have	inherited	different	haplotypes	from	the	father	resulting	in	sibling	1	being	an	8/10	
match	and	sibling	2	being	a	10/10	match	for	the	patient.	
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C*05 
B*44 
DRB1*04 
DQB1*03 
A*01 
C*07 
B*08 
DRB1*03 
DQB1*02 
A*02 
C*05  
B*44 
DRB1*04 
DQB1*03 
A*01 
C*07 
B*08 
DRB1*03 
DQB1*02 
Pa+ent	 Sib	1	 Sib	2	
a	 b	 c	 d	
a/b	 c	 a/b	a/b	c	 c	
A*02:01 
C*05:01 
B*44:02 
DRB1*04:04 
DQB1*03:02 
A*02:01 
C*05:01 
B*44:02 
DRB1*04:01 
DQB1*03:01 
A*01:01 
C*07:01 
B*08:01 
DRB1*03:01
DQB1*02:01 
A*11:01 
C*03:03 
B*55:01 
DRB1*14:54 
DQB1*05:03 
Father	 Mother	
A*02:01 
C*05:01 
B*44:02 
DRB1*04:01 
DQB1*03:01 
A*01:01 
C*07:01 
B*08:01 
DRB1*03:01 
DQB1*02:01 
A*02:01 
C*05:01 
B*44:02 
DRB1*04:04 
DQB1*03:02 
A*01:01 
C*07:01 
B*08:01 
DRB1*03:01 
DQB1*02:01 
A*02:01 
C*05:01  
B*44:02 
DRB1*04:01 
DQB1*03:01 
A*01:01 
C*07:01 
B*08:01 
DRB1*03:01 
DQB1*02:01 
Pa+ent	 Sib	1	is	a	8/10	
match	for	pa+ent	
Sib	2	
matches	pa+ent	
a	 b	 c	 d	
a	 c	 a	b	c	 c	
